ANGPTL4 gene modified non-human animal

A genetically modified animal model expressing human or chimeric ANGPTL4 protein addresses the limitations of traditional drug development methods by mimicking human body environments, improving drug screening and evaluation accuracy and reducing costs.

CN119061068APending Publication Date: 2024-12-03BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411336932.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-23
Filing Date
2024-09-25
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Traditional drug development methods using in vitro and conventional animal models fail to replicate the human body environment, leading to high failure rates and discrepancies between animal test results and clinical trials due to differences in tumor microenvironments and immune cell interactions.

Method used

Development of a genetically modified non-human animal model expressing human or chimeric ANGPTL4 protein, which mimics human ANGPTL4 function and interactions, allowing for more accurate drug screening and evaluation.

Benefits of technology

The animal model enhances drug development efficiency and reduces costs by providing a platform for studying ANGPTL4 function and screening drugs for tumors, inflammation, and metabolic diseases, with applications in pharmacodynamics research and therapeutic strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061068A_ABST
    Figure CN119061068A_ABST
Patent Text Reader

Abstract

The present invention provides a non-human animal expressing a human or chimeric (e.g., humanized) ANGPTL4 protein and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention provides a non-human animal expressing a human or chimeric (eg, humanized) ANGPTL4 protein and methods of use thereof. Background Art

[0002] Traditional drug development usually uses in vitro screening methods, but these screening methods cannot provide the body environment (such as tumor microenvironment, stromal cells, extracellular matrix components and immune cell interactions, etc.), resulting in a high failure rate of drug development. In addition, given the differences between humans and animals, the test results obtained from in vivo pharmacology tests using conventional experimental animals may not reflect the actual disease state and the interaction of the target site, resulting in significant differences between the results of many clinical trials and the results of animal experiments.

[0003] Therefore, developing a humanized animal model suitable for screening and evaluation of human antibodies will significantly improve the efficiency of new drug development and reduce the cost of drug development.

[0004] However, the construction of humanized animal models is very difficult. For example, the non-patent literature: Generation and utility of genetically humanized mouse models (Scheer N, Snaith M, Wolf CR, Seibler J., Drug Discovery Today; 18(23-24): 1200-11, 2013) discloses that the humanization of any gene carries certain risks, and even with carefully designed strategies, the expression and function of human genes in animals cannot be ensured. Summary of the invention

[0005] The present application provides an animal model with human or chimeric ANGPTL4 protein. The animal model can express human or chimeric ANGPTL4 (e.g., humanized ANGPTL4) protein. It can be used for the study of ANGPTL4 gene function, and can also be used for the screening and evaluation of ANGPTL4 signaling pathway regulators (e.g., anti-ANGPTL4 antibodies, nucleic acid drugs (e.g., oligonucleotide drugs) and / or polypeptide drugs). In addition, the animal model prepared by the method can be used for drug screening, pharmacodynamics research, treatment of diseases (especially tumors, inflammation, immune-related diseases or metabolic diseases) and treatment of diseases at human ANGPTL4 target sites; the animal model can also be used to promote new drug development and design, saving time and cost. In summary, the present invention provides a powerful tool for studying the function of ANGPTL4 protein and provides a platform for screening drugs for the treatment of related diseases.

[0006] In one aspect, the present invention provides a genetically modified non-human animal or a method for constructing the same, wherein the genome of the non-human animal comprises at least one chromosome, wherein the chromosome comprises a nucleotide sequence encoding a human or chimeric angiopoietin-like protein 4 (ANGPTL4) protein. In some embodiments, the nucleotide sequence encoding the human or chimeric ANGPTL4 protein is operably linked to an endogenous regulatory element or a human regulatory element (e.g., 5'UTR, 3'UTR and / or promoter) of an endogenous ANGPTL4 locus of at least one chromosome. In some embodiments, the chimeric ANGPTL4 protein is a humanized ANGPTL4 protein, wherein the humanized ANGPTL4 protein comprises at least 50 to at least 406 consecutive amino acid sequences identical to a human ANGPTL4 protein. In some embodiments, the amino acid sequence of the human or chimeric ANGPTL4 protein comprises SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that differs from SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, comprises an amino acid sequence that is substituted, deleted and / or inserted with one or more amino acids as shown in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406. In some embodiments, the non-human animal is a mammal, such as a monkey or a rodent (e.g., a mouse or rat). In some embodiments, the non-human animal is a mouse. In some embodiments, the non-human animal does not express endogenous ANGPTL4 protein or expresses reduced levels of ANGPTL4 compared to wild-type animals. In some embodiments, one or more cells of the non-human animal express human or chimeric ANGPTL4 protein.

[0007] In one aspect, the present invention provides a genetically modified non-human animal or a method for constructing the same, comprising replacing an endogenous ANGPTL4 gene of a non-human animal with a nucleotide sequence comprising human ANGPTL4 at the endogenous ANGPTL4 locus of the non-human animal (e.g., replacement of the corresponding regions of the human and non-human animal). In some embodiments, the nucleotide sequence of human ANGPTL4 is operably linked to an endogenous regulatory element or a human regulatory element (e.g., 5'UTR, 3'UTR and / or promoter) of the endogenous ANGPTL4 locus. In some embodiments, one or more cells of the non-human animal express a human or chimeric (e.g., humanized) ANGPTL4 protein. In some embodiments, the endogenous ANGPTL4 protein of the non-human animal is not expressed or is expressed at a reduced level compared to ANGPTL4 in wild-type animals. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises all or part of exon 1, all of exons 2-6, and / or all or part of exon 7 of the human ANGPTL4 gene, wherein the part of exon 1 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence; the part of exon 7 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of the coding region of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR and / or 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR of the human ANGPTL4 gene and at least 50 bp of consecutive nucleotides upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and at least 50 bp of consecutive nucleotides downstream of the 3'UTR, or, the nucleotide sequence of human ANGPTL4 comprises a portion of exon 1 to a portion of exon 7 of the human ANGPTL4 gene.In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that is substituted, deleted and / or inserted with one or more nucleotides as shown in the nucleotide sequence of SEQ ID NO: 5 or 16. In some embodiments, the non-human animal is a mammal, such as a monkey or a rodent (e.g., a mouse or a rat). In some embodiments, the non-human animal is a mouse. In some embodiments, the mRNA transcribed from the modified nucleotide sequence of endogenous ANGPTL4 in the genome of the non-human animal comprises the nucleotide sequence of SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 13 or 21 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that is substituted, deleted and / or inserted with one or more nucleotides as shown in the nucleotide sequence of SEQ ID NO: 13 or 21. In some embodiments, all or part of exon 1, all of exons 2-6 and / or all or part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal are replaced. In some embodiments, the replaced endogenous ANGPTL4 gene of the non-human animal further comprises at least 50 bp of continuous nucleotides upstream of the 5'UTR and / or at least 50 bp of continuous nucleotides downstream of the 3'UTR of the endogenous ANGPTL4 gene. In some embodiments, a portion of exon 1 to a portion of exon 7 of the endogenous ANGPTL4 gene of the non-human animal is replaced, wherein the portion of exon 1 of the endogenous ANGPTL4 gene of the non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence; the portion of exon 7 of the endogenous ANGPTL4 gene of the non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the endogenous ANGPTL4 gene to at least 50 bp of continuous nucleotides downstream of the 3'UTR is replaced. In some embodiments, the modified ANGPTL4 gene in the genome of the non-human animal is homozygous or heterozygous for the endogenous replaced locus.In some embodiments, the non-human animal further comprises nucleotide sequences of human or chimeric proteins encoded by other genes, wherein the human or chimeric proteins comprise at least one of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA-4.

[0008] In one aspect, the present invention provides a non-human animal or method of constructing the same, comprising at least one cell comprising a nucleotide sequence encoding a human or chimeric (e.g., humanized) ANGPTL4 protein, wherein the human or chimeric ANGPTL4 protein comprises at least 50, 60, 70, 80, 90, 100, 200, 300, 350, 370, 375, 376, 377, 400, 401, 402, 403, 404, 405, or 406 consecutive amino acids identical to a human ANGPTL4 protein. In some embodiments, the nucleotide sequence encoding the human or chimeric ANGPTL4 protein is operably linked to an ANGPTL4 regulatory element, such as an endogenous or human ANGPTL4 regulatory element. In some embodiments, the nucleotide sequence encoding the human or chimeric ANGPTL4 protein is operably integrated into the endogenous ANGPTL4 locus of the non-human animal. In some embodiments, the human or chimeric ANGPTL4 protein has at least one ANGPTL4 activity, such as a non-human animal ANGPTL4 activity and / or a human ANGPTL4 activity.

[0009] In one aspect, the present invention provides a method for constructing a genetically modified non-human animal. In some embodiments, the non-human animal expresses a human or chimeric ANGPTL4 protein. In some embodiments, at the endogenous ANGPTL4 locus of the non-human animal, a nucleotide sequence comprising human ANGPTL4 is substituted for the endogenous ANGPTL4 gene of the non-human animal (e.g., replacement of the corresponding regions of the human and non-human animal). In some embodiments, the endogenous ANGPTL4 protein of the non-human animal is not expressed or the expression level is reduced compared to ANGPTL4 in wild-type animals. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises all or part of exon 1, all of exons 2-6, and / or all or part of exon 7 of the human ANGPTL4 gene, wherein the portion of exon 1 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence; the portion of exon 7 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of the coding region of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises a nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR and / or 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR, or the nucleotide sequence of human ANGPTL4 comprises a portion of exon 1 to a portion of exon 7 of the human ANGPTL4 gene.In some embodiments, the nucleotide sequence of human ANGPTL4 encodes an amino acid sequence comprising SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2; or, comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence as shown in SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2; or, comprises an amino acid sequence that differs from SEQ ID NO: 2 or positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, comprises an amino acid sequence that substitutes, deletes and / or inserts one or more amino acids as shown in SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that is substituted, deleted and / or inserted with one or more nucleotides as shown in the nucleotide sequence of SEQ ID NO: 5 or 16. In some embodiments, all or part of exon 1, all of exons 2-6 and all or part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal are replaced. In some embodiments, the replaced endogenous ANGPTL4 gene of a non-human animal further comprises at least 50 bp of continuous nucleotides upstream of the 5'UTR and / or at least 50 bp of continuous nucleotides downstream of the 3'UTR of the endogenous ANGPTL4 gene. In some embodiments, a portion of exon 1 to a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal is replaced, wherein the portion of exon 1 of an endogenous ANGPTL4 gene of a non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence; the portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the endogenous ANGPTL4 gene to a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR is replaced. In some embodiments, the nucleotide sequence of human ANGPTL4 is operably linked to an ANGPTL4 regulatory element of an ANGPTL4 locus of at least one chromosome, such as an endogenous or human regulatory element, such as a promoter.In some embodiments, the non-human animal is a mammal, such as a monkey or a rodent (e.g., a mouse or a rat). In some embodiments, the non-human animal is a mouse. In some embodiments, the non-human animal further comprises a nucleotide sequence of a human or chimeric protein encoded by other genes, wherein the human or chimeric protein comprises at least one of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA-4.

[0010] In one aspect, the present invention provides a method for constructing a genetically modified non-human animal cell expressing human or chimeric ANGPTL4, the construction method comprising replacing the endogenous ANGPTL4 gene of the non-human animal with a nucleotide sequence comprising human ANGPTL4 at the endogenous ANGPTL4 locus of the non-human animal (e.g., replacement of the corresponding regions of human and non-human animals). In some embodiments, the nucleotide sequence of human ANGPTL4 comprises all or part of exon 1, all of exons 2-6, and / or all or part of exon 7 of the human ANGPTL4 gene, wherein the part of exon 1 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence; the part of exon 7 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of the coding region of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR and / or 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the 5'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, a nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR, or the nucleotide sequence of human ANGPTL4 comprises a portion of exon 1 to a portion of exon 7 of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence of human ANGPTL4 encodes an amino acid sequence comprising SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2; or, comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence as shown in SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2; or, comprises an amino acid sequence that differs from SEQ ID NO: 2 or positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, comprises an amino acid sequence that substitutes, deletes and / or inserts one or more amino acids as shown in SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2.In some embodiments, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that is substituted, deleted and / or inserted with one or more nucleotides as shown in the nucleotide sequence of SEQ ID NO: 5 or 16. In some embodiments, all or part of exon 1, all of exons 2-6 and / or all or part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal are replaced. In some embodiments, the replaced endogenous ANGPTL4 gene of a non-human animal further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the endogenous ANGPTL4 gene of the non-human animal and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR. In some embodiments, the replaced endogenous ANGPTL4 gene of a non-human animal further comprises at least 50 bp of continuous nucleotides upstream of the 5'UTR of the endogenous ANGPTL4 gene of the non-human animal and / or at least 50 bp of continuous nucleotides downstream of the 3'UTR. In some embodiments, a portion of exon 1 to a portion of exon 7 of the endogenous ANGPTL4 gene of a non-human animal is replaced, wherein the portion of exon 1 of the endogenous ANGPTL4 gene of the non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence; the portion of exon 7 of the endogenous ANGPTL4 gene of the non-human animal preferably comprises at least 50 bp of continuous nucleotide sequence. In some embodiments, a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the endogenous ANGPTL4 gene of a non-human animal to a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the endogenous ANGPTL4 gene of a non-human animal is replaced. In some embodiments, the nucleotide sequence of human ANGPTL4 is operably linked to a regulatory element of ANGPTL4, such as an endogenous regulatory element or a human regulatory element, such as a promoter. In some embodiments, the expression of the nucleotide sequence of human ANGPTL4 is through a regulatory element, such as an endogenous regulatory element or a human regulatory element, such as a promoter. In some embodiments, the non-human animal is a mammal, such as a monkey or a rodent (e.g., a rat or a mouse). In some embodiments, the non-human animal is a mouse.In some embodiments, the non-human animal further comprises nucleotide sequences of human or chimeric proteins encoded by other genes, wherein the human or chimeric proteins include at least one of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA-4.

[0011] In one aspect, the present invention provides a method for determining the effectiveness of a therapeutic agent in treating a disease, the method comprising: 1) administering a therapeutic agent to a non-human animal obtained by the above construction method, wherein the non-human animal suffers from a disease; 2) determining the inhibitory effect of the therapeutic agent on the disease. In some embodiments, the therapeutic agent comprises an ANGPTL4 therapeutic agent. In some embodiments, the ANGPTL4 therapeutic agent comprises an anti-ANGPTL4 antibody, a polypeptide drug, or a nucleic acid drug, such as an ASO. In some embodiments, the therapeutic agent further comprises an additional therapeutic agent. In some embodiments, the additional therapeutic agent comprises one or more of an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. In some embodiments, the disease comprises one or more of a tumor, a metabolic disease, an inflammation, or an immune-related disease. In some embodiments, the tumor comprises one or more of melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, kidney cancer, breast cancer, or endocrine cancer. In some embodiments, the metabolic disease comprises one or more of obesity, non-alcoholic fatty liver disease (NAFLD), or atherosclerosis. In some embodiments, the immune-related diseases include one or more of GVHD (graft versus host disease), psoriasis, allergy, asthma, myocarditis, nephritis, hepatitis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, atopic dermatitis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain or neurological disorders. In some embodiments, the inflammation includes but is not limited to one or more of myocarditis, nephritis, hepatitis, rheumatoid arthritis, atopic dermatitis or ulcerative colitis.

[0012] In one aspect, the present invention provides a method for determining the effectiveness of a therapeutic agent in treating a disease, the method comprising:

[0013] 1) administering an ANGPTL4 therapeutic agent to the non-human animal or the non-human animal obtained by the above construction method, wherein the non-human animal suffers from a disease; 2) determining the inhibitory effect of the therapeutic agent on the disease. In some embodiments, the disease comprises one or more of a tumor, a metabolic disease, an inflammation, or an immune-related disease. In some embodiments, the therapeutic agent comprises an anti-ANGPTL4 antibody, a polypeptide drug, or a nucleic acid drug (the nucleic acid drug is, for example, an ASO). In some embodiments, determining the inhibitory effect of the therapeutic agent on the disease comprises measuring the tumor volume in the non-human animal. In some embodiments, the tumor includes, but is not limited to, one or more of melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, kidney cancer, breast cancer, or endocrine cancer. In some embodiments, the metabolic disease includes, but is not limited to, one or more of obesity, non-alcoholic fatty liver disease (NAFLD), or atherosclerosis. In some embodiments, the immune-related diseases include, but are not limited to, one or more of GVHD (graft versus host disease), psoriasis, allergy, asthma, myocarditis, nephritis, hepatitis (preferably non-alcoholic fatty liver disease), systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, atopic dermatitis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain, or neurological disorders. In some embodiments, the inflammation includes, but is not limited to, one or more of myocarditis, nephritis, hepatitis, rheumatoid arthritis, atopic dermatitis, or ulcerative colitis.

[0014] In one aspect, the present invention provides a method for determining the effectiveness of anti-ANGPTL4 therapeutic agents and other therapeutic agents in treating a disease, the method comprising: 1) administering an ANGPTL4 therapeutic agent and other therapeutic agents to the non-human animal or the non-human animal obtained by the above-mentioned construction method, wherein the non-human animal suffers from a disease; 2) determining the inhibitory effect on the disease. In some embodiments, the anti-ANGPTL4 therapeutic agent comprises an anti-ANGPTL4 antibody, a polypeptide drug or a nucleic acid drug, such as an ASO; in some embodiments, the non-human animal further comprises a sequence encoding human or chimeric PD-1, human or chimeric PD-L1 and / or human or chimeric CTLA-4. In some embodiments, the other therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody and / or an anti-CTLA-4 antibody. In some embodiments, the tumor comprises one or more tumor cells expressing PD-L1. In some embodiments, the tumor includes, but is not limited to, one or more of melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, kidney cancer, breast cancer or endocrine cancer. In some embodiments, determining the inhibitory effect on the disease comprises measuring the tumor volume in the non-human animal. In certain embodiments, the metabolic disease includes but is not limited to one or more of obesity, non-alcoholic fatty liver disease (NAFLD) or atherosclerosis. In certain embodiments, the immune-related disease includes but is not limited to GVHD (graft versus host disease), psoriasis, allergy, asthma, myocarditis, nephritis, hepatitis (preferably non-alcoholic fatty liver disease), systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, atopic dermatitis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain or neurological disorders. In certain embodiments, the inflammation includes but is not limited to one or more of myocarditis, nephritis, hepatitis, rheumatoid arthritis, atopic dermatitis or ulcerative colitis.

[0015] In one aspect, the present invention provides a method for determining the toxicity of an ANGPTL4 therapeutic agent, the method comprising: 1) administering an ANGPTL4 therapeutic agent to the non-human animal or the non-human animal obtained by the above-mentioned construction method; 2) determining the effect of the ANGPTL4 therapeutic agent on the non-human animal. In some embodiments, the determining the effect of the ANGPTL4 therapeutic agent on the non-human animal comprises measuring the weight of the animal or performing a blood test. In some embodiments, the blood test comprises one or more of red blood cell count, hematocrit, or hemoglobin content.

[0016] In one aspect, the present invention provides a humanized ANGPTL4 gene, the humanized ANGPTL4 gene comprising any of the following nucleotide sequences: A) encoding SEQ ID NO: 2 or a nucleotide sequence at positions 31-406 of SEQ ID NO: 2; B) one or more of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23; C) a nucleotide sequence that is at least 90% identical to one or more of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23; D) a nucleotide sequence that is at least 90% identical to SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23. A nucleotide sequence having at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to one or more of NO:3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.

[0017] In one aspect, a targeting vector is provided, the targeting vector comprising a 5' arm, a donor sequence and a 3' arm, wherein the 5' arm is homologous to the 5' end of the switch region to be changed, the 3' arm is homologous to the 3' end of the switch region to be changed, and the donor sequence comprises a nucleotide sequence encoding a human or chimeric ANGPTL4 protein. In some embodiments, the switch region to be changed is located at an endogenous ANGPTL4 locus of a non-human animal. In some embodiments, the switch region to be changed includes at least one exon and / or at least one intron of an endogenous ANGPTL4 gene of a non-human animal, such as a portion of exon 1 to a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal, or at least 50 bp upstream of the 5'UTR to at least 50 bp downstream of the 3'UTR of an endogenous ANGPTL4 gene of a non-human animal. In some embodiments, the 5' end of the switch region to be changed is located at exon 1 of an endogenous ANGPTL4 gene of a non-human animal, and / or the 3' end of the switch region to be changed is located at exon 7 of an endogenous ANGPTL4 gene of a non-human animal. In some embodiments, the 5' end of the switch region to be altered is located at least 50 bp upstream of the 5'UTR of the endogenous ANGPTL4 gene of the non-human animal, and / or the 3' end of the switch region to be altered is located at least 50 bp downstream of the 3'UTR of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, the 5' arm sequence is as described in SEQ ID NO:3, and the 3' arm sequence is as described in SEQ ID NO:4. In some embodiments, the 5' arm sequence is as described in SEQ ID NO:10, and the 3' arm sequence is as described in SEQ ID NO:11. In some embodiments, the 5' arm sequence is as described in SEQ ID NO:14, and the 3' arm sequence is as described in SEQ ID NO:15. In some embodiments, the 5' arm sequence is as described in SEQ ID NO:22, and the 3' arm sequence is as described in SEQ ID NO:23. In some embodiments, the chimeric ANGPTL4 protein is a humanized ANGPTL4 protein, which comprises a portion of a human ANGPTL4 protein and a non-human animal ANGPTL4 protein. In some embodiments, the human or chimeric ANGPTL4 protein comprises at least 50 to at least 406 consecutive amino acids identical to a human ANGPTL4 protein.In some embodiments, the amino acid sequence of the human or chimeric ANGPTL4 protein comprises SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that differs from SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, comprises an amino acid sequence that is substituted, deleted and / or inserted with one or more amino acids as set forth in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406. In some embodiments, the donor sequence comprises all or part of exon 1, all of exons 2-6 and / or all or part of exon 7 of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises a nucleotide sequence of the coding region of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises a nucleotide sequence from the start codon to the stop codon of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises the 5'UTR and / or 3'UTR of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of a human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises the 5'UTR of a human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of a human ANGPTL4 gene, and the 3'UTR of a human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR. In some embodiments, the donor sequence comprises a portion of exon 1 to a portion of exon 7 of a human ANGPTL4 gene. In some embodiments, the donor sequence comprises the nucleotide sequence shown in SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence shown in SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence shown in SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that substitutes, deletes and / or inserts one or more nucleotides as shown in the nucleotide sequence shown in SEQ ID NO: 5 or 16.

[0018] In one aspect, the present invention provides a cell, tissue or organ, comprising the above-mentioned humanized ANGPTL4 gene.

[0019] In one aspect, the present invention provides an animal model, wherein the animal model comprises the above-mentioned humanized ANGPTL4 gene.

[0020] In one aspect, a use of the above non-human animal, the non-human animal obtained by the above construction method, the cell obtained by the above construction method, the humanized ANGPTL4 gene, the cell, tissue or organ, the targeting vector or the animal model is provided. In some embodiments, the use includes A) the use in the development of products involving ANGPTL4-related immune processes in human cells; B) the use as a model system related to ANGPTL4 in pharmacology, immunology, microbiology and medical research; C) the use of producing and using animal experimental disease models for ANGPTL4-related etiology research and / or for developing diagnostic strategies and / or for developing therapeutic strategies; D) the use in the screening, efficacy detection, efficacy evaluation, verification or evaluation of human ANGPTL4 signaling pathway regulators in vivo; or, E) the use in studying the function of the ANGPTL4 gene, studying drugs and efficacy targeting human ANGPTL4 target sites, and studying drugs for tumors, metabolic diseases, inflammation, and immune-related diseases related to ANGPTL4.

[0021] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those of ordinary skill in the art to which the invention belongs. This application describes methods and materials for use in the present invention; other suitable methods and materials known in the art may be used. The materials, methods, and examples are exemplary and non-limiting only. All publications, patent applications, patents, sequences, database entries, and other references mentioned in this application are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0022] The term "all or part" in the present invention, "all" refers to the whole, and "part" refers to a part of the whole, or an individual part that constitutes the whole.

[0023] The term "locus" in the present invention refers to the position of a gene on a chromosome in a broad sense, and refers to a DNA fragment on a gene in a narrow sense, which can be a gene or a part of a gene. For example, the "ANGPTL4 locus" refers to a DNA fragment selected from exons 1 to 7 of the ANGPTL4 gene. In some embodiments, the replaced endogenous ANGPTL4 locus of a non-human animal can be a DNA fragment selected from exons 1 to 7 of the endogenous ANGPTL4 gene of a non-human animal.

[0024] The term "portion of exon XX" of the present invention means that continuous or intervening several, dozens or hundreds of nucleotide sequences are consistent with the entire exon nucleotide sequence, for example, a portion of exon 1 of the human ANGPTL4 gene, including continuous or intervening 5-485, for example 5, 10, 50, 100, 150, 200, 250, 300, 310, 318, 320, 350, 400, 450, 480 or 485 bp nucleotide sequences that are consistent with the nucleotide sequence of exon 1 of the human ANGPTL4 gene.

[0025] The term "exon XX to exon XXX" or "exon XX-XXX" of the present invention refers to exons and introns in between, for example, exon 1 to exon 7 includes the entire nucleotide sequence of exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, and exon 7.

[0026] The term "portion of exon XX to portion of exon XXX" in the present invention refers to the nucleotide sequence from a portion of one exon to a portion of another exon and the introns in between, for example, the portion of exon 1 to the portion of exon 7 includes a portion of exon 1, all of intron 1, all of exon 2, all of intron 2, all of exon 3, all of intron 3, all of exon 4, all of intron 4, all of exon 5, all of intron 5, all of exon 6, all of intron 6, and a portion of the nucleotide sequence of exon 7.

[0027] The term "intron xx" of the present invention refers to an intron between two exons, for example, intron 1 is an intron between exon 1 and exon 2.

[0028] The term "comprising" or "including" in the present invention is an open-ended writing method, which contains the specified components or steps described, as well as other specified components or steps that will not be substantially affected. When used to describe a protein or nucleic acid sequence, the protein or nucleic acid may be composed of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the same or similar activity as the original sequence.

[0029] The term "and / or" of the present invention includes all combinations of items connected by the term, and each combination should be deemed to have been listed separately in the present application. For example, "A and / or B" includes "A", "A and B" and "B". For another example, "A, B and / or C" includes "A", "B", "C", "A and B", "A and C", "B and C" and "A and B and C".

[0030] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description as described below.

[0031] Detailed description

[0032] ANGPTL4

[0033] In the human genome, the ANGPTL4 gene (Gene ID: 51129) contains 7 exons, namely exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and exon 7 ( Figure 1 ). The nucleotide sequence of human ANGPTL4 mRNA is NM_139314.3, and the amino acid sequence of human ANGPTL4 is NP_647475.1 (SEQ ID NO: 2). The corresponding position of each exon in the nucleotide sequence and amino acid sequence of the transcript NM_139314.3 and its encoded protein NP_647475.1 is shown in Table 1:

[0034] Table 1

[0035]

[0036]

[0037] In the mouse genome, the ANGPTL4 gene (Gene ID: 57875) contains 7 exons, namely exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and exon 7 ( Figure 1 ). The nucleotide sequence of mouse ANGPTL4 mRNA is NM_020581.2, and the amino acid sequence of mouse ANGPTL4 is NP_065606.2 (SEQ ID NO: 1). The corresponding position of each exon in the nucleotide sequence and amino acid sequence of the transcript NM_020581.2 and its encoded protein NP_065606.2 is shown in Table 2:

[0038] Table 2

[0039]

[0040] ANGPTL4 genes, proteins and gene loci of other species are also known in the art. For example, Rattus norvegicus (rat) ANGPTL4 Gene ID: 362850, Macaca mulatta (rhesus monkey) ANGPTL4 Gene ID: 711693, Canis lupus familiaris (dog) ANGPTL4 Gene ID: 476724, Sus scrofa (pig) ANGPTL4 Gene ID: 397628. The relevant information of these genes (such as intron sequence, exon sequence and amino acid sequence) can be found in NCBI, and the entire contents are incorporated into this application by reference.

[0041] The present invention provides a human or chimeric (e.g., humanized) ANGPTL4 protein, or a human or chimeric (e.g., humanized) ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 protein comprises a portion of a human ANGPTL4 protein. In some embodiments, the humanized ANGPTL4 protein further comprises a portion of a non-human animal ANGPTL4 protein. In some embodiments, the humanized ANGPTL4 protein comprises an amino acid sequence that is identical to at least 50 to at least 406 (e.g., 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 370, 375, 376, 377, 400, or 406) consecutive amino acid sequences of a human ANGPTL4 protein. In some embodiments, the humanized ANGPTL4 protein has an amino acid sequence comprising SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, an amino acid sequence that differs from SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, an amino acid sequence that comprises a substitution, deletion and / or insertion of one or more amino acids as set forth in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406.

[0042] In some embodiments, the humanized ANGPTL4 gene encodes the humanized ANGPTL4 protein described above. In some embodiments, the humanized ANGPTL4 gene comprises a portion of a human ANGPTL4 gene and a portion of a non-human animal ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene may be a genomic sequence, a CDS or a cDNA sequence. In some embodiments, the portion of the human ANGPTL4 gene comprises at least one exon and / or at least one intron of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises all or part of exon 1, all of exons 2-6 and / or all or part of exon 7 of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises the nucleotide sequence of the coding region of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises the 5'UTR and / or 3'UTR of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises the 5'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, a nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR. In some embodiments, the portion of the human ANGPTL4 gene comprises a portion of exon 1 to a portion of exon 7 of the human ANGPTL4 gene. In some embodiments, the portion of the human ANGPTL4 gene comprises the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that substitutes, deletes and / or inserts one or more nucleotides from the nucleotide sequence of SEQ ID NO: 5 or 16.

[0043] In some embodiments, the humanized ANGPTL4 gene includes, from the 5' end to the 3' end, part of exon 1 of a non-human animal ANGPTL4 gene, part of exon 1 of a human ANGPTL4 gene, all of exons 2-6 of a human ANGPTL4 gene, part of exon 7 of a human ANGPTL4 gene, and part of exon 7 of a non-human animal ANGPTL4 gene (preferably also including intron 1 and intron 6 of a human ANGPTL4 gene). In some embodiments, the humanized ANGPTL4 gene includes, from the 5' end to the 3' end, the 5'UTR of the human ANGPTL4 gene and the nucleotide sequence upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and the nucleotide sequence downstream of the 3'UTR.

[0044] In some embodiments, the humanized ANGPTL4 gene comprises, from 5' to 3' end, A) SEQ ID NO: 3, 5, 4; B) SEQ ID NO: 3, 16, 4; C) SEQ ID NO: 10, 5, 11; D) SEQ ID NO: 10, 16, 11; E) SEQ ID NO: 14, 5, 15; F) SEQ ID NO: 14, 16, 15; G) SEQ ID NO: 22, 5, 23; H) SEQ ID NO: 22, 16, 23. In some embodiments, the humanized ANGPTL4 gene comprises one or more of SEQ ID NO: 6, 7, 8, 9, 17, 18, 19 or 20.

[0045] In some embodiments, the mRNA transcribed from the humanized ANGPTL4 gene comprises the nucleotide sequence of SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that differs from the nucleotide sequence of SEQ ID NO: 13 or 21 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that substitutes, deletes and / or inserts one or more nucleotides from the nucleotide sequence of SEQ ID NO: 13 or 21.

[0046] In some embodiments, the humanized ANGPTL4 gene comprises a resistance gene. In some embodiments, the resistance gene is a neomycin phosphotransferase coding sequence Neo. In some embodiments, the humanized ANGPTL4 gene comprises a negative selection marker. In some embodiments, the coding gene of the negative selection marker is a gene encoding the diphtheria toxin A subunit (DTA). In some embodiments, the humanized ANGPTL4 gene further comprises two Frt sites arranged in the same direction on both sides of the resistance gene. In some embodiments, the humanized ANGPTL4 gene further comprises a specific inducer or repressor, and the specific inducer or repressor is preferably a conventional substance that can be induced or repressed. In some embodiments, the specific inducer includes but is not limited to a tetracycline system (Tet-Off System / Tet-On System) or a tamoxifen system (Tamoxifen System). In some embodiments, the humanized ANGPTL4 gene is regulated in a non-human animal by a regulatory element. In some embodiments, the regulatory element is an endogenous regulatory element or an exogenous regulatory element (e.g., a human regulatory element). In some embodiments, the regulatory element is one or more of a 5'UTR, a 3'UTR, or a promoter.

[0047] In some embodiments, the non-human animal expresses a human or chimeric (e.g., humanized) ANGPTL4 protein, or the genome of the non-human animal comprises a human or chimeric (e.g., humanized) ANGPTL4 gene, by replacing the nucleotide sequence of a human ANGPTL4 with the endogenous ANGPTL4 gene of the non-human animal (e.g., replacement of the corresponding positions of the human and non-human animals).

[0048] In some embodiments, all or part of the nucleotide sequence or the encoded amino acid sequence of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 of the endogenous ANGPTL4 gene of the non-human animal is replaced by the corresponding nucleotide sequence or the encoded amino acid sequence of the human ANGPTL4 gene.

[0049] In some embodiments, all or part of the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence or the encoded amino acid sequence of the endogenous ANGPTL4 gene of a non-human animal is replaced by the corresponding nucleotide sequence or the encoded amino acid sequence of the human ANGPTL4 gene. In some embodiments, all or part of the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence or the encoded amino acid sequence of the endogenous ANGPTL4 gene of a non-human animal is replaced by the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence or the encoded amino acid sequence of the human ANGPTL4 gene.

[0050] In some embodiments, the 5'UTR upstream nucleotide sequence of the human ANGPTL4 gene comprises at least 50-8000 bp, such as 50, 100, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000 or 8000 bp nucleotide sequence. In some embodiments, the 5'UTR upstream nucleotide sequence of the human ANGPTL4 gene comprises a nucleotide sequence of 100-500 bp, 1000-3000 bp or 5000-8000 bp. In some embodiments, the 3'UTR downstream nucleotide sequence of the human ANGPTL4 gene comprises at least 50-1000 bp, for example, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 577, 600, 650, 700, 750, 800, 900, 1000 bp of nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the human ANGPTL4 gene comprises 400-700 bp.

[0051] In some embodiments, the 5'UTR upstream nucleotide sequence of the endogenous ANGPTL4 gene of the non-human animal comprises at least 50-6000 bp, such as 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 3000, 4000, 4400, 4600, 4700, 4720, 4740, 4743, 4800, 4900, 5000, 5500 or 6000 bp of continuous nucleotides. In some embodiments, the 5'UTR upstream nucleotide sequence of the endogenous ANGPTL4 gene of the non-human animal comprises 100-500 bp, 1000-2000 bp or 3000-5000 bp of continuous nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the endogenous ANGPTL4 gene of a non-human animal comprises at least 5-300 bp of consecutive nucleotides, such as 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 100, 200 or 300 bp of consecutive nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the endogenous ANGPTL4 gene of a non-human animal comprises 50-100 bp of consecutive nucleotides.

[0052] In some embodiments, a “portion” of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, and / or exon 7 of an endogenous ANGPTL4 gene in a non-human animal refers to at least 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1210, 1220, 1233, 1231, 1232, 1233, 1500, 1800, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1920, 1921, 1922, 1923, 1924, 1925, 1926, 1927, 1928, 1929, 1930, 1931 910, 1912, 1914, 1915, 1916, 2000, 3000, 4000, 5000, 6000, 6500, 6676, 7000, 8000, 9000, 10000, 11000, 11419, 11420, 11500, 11510 or 11511 bp continuous nucleotide sequence, or an amino acid sequence encoded by it of at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 410 consecutive amino acid sequences. In some embodiments, the “portion” is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 99% identical to the nucleotide sequence or the encoded amino acid sequence of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 of an endogenous ANGPTL4 gene of a non-human animal. In some embodiments, the “portion” is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or at least 99% identical to the nucleotide sequence upstream of the 5'UTR to the nucleotide sequence downstream of the 3'UTR of an endogenous ANGPTL4 gene of a non-human animal.

[0053] In some embodiments, "partial" or "complete" sequences of exon 1 (including 5'UTR), exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 (including 3'UTR) of a non-human animal ANGPTL4 gene (e.g., part of exon 1, all of exons 2-6 and part of exon 7 of a non-human animal ANGPTL4 gene) are replaced by "partial" or "complete" sequences of corresponding exon 1 (including 5'UTR), exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 (including 3'UTR) of a human ANGPTL4 gene (e.g., part of exon 1, all of exons 2-6 and part of exon 7 of a human ANGPTL4 gene).

[0054] In some embodiments, "part" or "all" of the 5'UTR upstream nucleotide sequence, exon 1 (including 5'UTR), exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 (including 3'UTR) and / or the 3'UTR downstream nucleotide sequence of the mouse ANGPTL4 gene (e.g., the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence of the non-human animal ANGPTL4 gene) is replaced by the corresponding 5'UTR upstream nucleotide sequence, exon 1 (including 5'UTR), exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 (including 3'UTR) and / or the 3'UTR upstream nucleotide sequence of the human ANGPTL4 gene (e.g., the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence of the human ANGPTL4 gene).

[0055] In some embodiments, "partial" deletion of the nucleotide sequence upstream of the 5'UTR, exon 1 (including the 5'UTR), intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7 (including the 3'UTR) and / or the nucleotide sequence downstream of the 3'UTR of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, the 5'UTR upstream nucleotide sequence of the non-human animal ANGPTL4 gene comprises at least 50-6000 bp, such as 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 3000, 4000, 4400, 4600, 4700, 4720, 4740, 4743, 4800, 4900, 5000, 5500 or 6000 bp of continuous nucleotides. In some embodiments, the 5'UTR upstream nucleotide sequence of the non-human animal ANGPTL4 gene comprises 100-500 bp, 1000-2000 bp or 3000-5000 bp of continuous nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the non-human animal ANGPTL4 gene contains at least 5-300bp, such as 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 100, 200 or 300bp of consecutive nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the non-human animal ANGPTL4 gene contains 50-100bp of consecutive nucleotides.

[0056] In some embodiments, a portion of exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, or exon 7 of an endogenous ANGPTL4 gene of a non-human animal is deleted. In some embodiments, the deleted portion of exon 1 of an endogenous ANGPTL4 gene of a non-human animal comprises at least 50-513 bp of continuous nucleotide sequence, such as 50, 60, 70, 80, 90, 100, 150, 160, 180, 182, 183, 200, 300, 310, 320, 330, 400, 500, 510, 511, 512, or 513 bp. In some embodiments, the deleted portion of exon 1 of an endogenous ANGPTL4 gene of a non-human animal comprises a nucleotide sequence of a coding region. In some embodiments, the portion of exon 7 of the non-human animal endogenous ANGPTL4 gene deleted comprises at least 50-669 bp of continuous nucleotide sequence, such as 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 181, 182, 200, 300, 500, 600, 620, 640, 660 or 669 bp. In some embodiments, the portion of exon 7 of the non-human animal endogenous ANGPTL4 gene deleted comprises the nucleotide sequence of the coding region.

[0057] In some embodiments, the present invention provides a genetically modified non-human animal, the genome of which comprises a human or chimeric (e.g., humanized) ANGPTL4 gene. In some embodiments, the protein encoded by the human or chimeric (e.g., humanized) ANGPTL4 gene comprises SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that is at least 70%, 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406. In some embodiments, the nucleotide sequence contained in the genome of the non-human animal includes one or more of the nucleotide sequences shown in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23; or includes a nucleotide sequence that is at least 70%, 80%, 85%, 90%, 95% or 99% identical to one or more of the nucleotide sequences shown in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.

[0058] In some embodiments, the non-human animal comprises a portion of a human ANGPTL4 gene or a humanized ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 gene comprises 7 exons. In some embodiments, the humanized ANGPTL4 gene comprises humanized exon 1, human exon 2, human exon 3, human exon 4, human exon 5, human exon 6 and / or humanized exon 7. In some embodiments, the humanized ANGPTL4 gene comprises human exon 1, human exon 2, human exon 3, human exon 4, human exon 5, human exon 6 and / or human exon 7. In some embodiments, the humanized ANGPTL4 gene comprises human intron 1, human intron 2, human intron 3, human intron 4, human intron 5 and / or human intron 6. In some embodiments, the humanized ANGPTL4 gene comprises a human or humanized or endogenous 5'UTR. In some embodiments, the humanized ANGPTL4 gene comprises a human or humanized or endogenous 3'UTR.

[0059] In some embodiments, the genetically modified non-human animal may express human ANGPTL4 and / or chimeric (e.g., humanized) ANGPTL4 proteins, wherein the endogenous ANGPTL4 gene sequence of the non-human animal is replaced by a human ANGPTL4 gene and / or nucleotide sequence. Further, the amino acid sequence encoded by the human ANGPTL4 gene and / or nucleotide sequence is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of the human ANGPTL4 protein as shown in SEQ ID NO: 2 or SEQ ID NO: 2 from position 31 to position 406. In some embodiments, the nucleotide sequence of the endogenous ANGPTL4 gene of the non-human animal is replaced by all or part of the nucleotide sequence encoding the mature human ANGPTL4 protein.

[0060] In some embodiments, the genetically modified non-human animal expresses human ANGPTL4 and / or chimeric ANGPTL4 protein (e.g., humanized ANGPTL4) under endogenous or human regulatory elements (e.g., 5'UTR, 3'UTR or promoter). Replacement of the endogenous locus provides a non-human animal that expresses human or chimeric ANGPTL4 protein (e.g., humanized ANGPTL4) in the same type of cells. The genetically modified non-human animal does not show potential diseases observed in certain other transgenic non-human animals known in the art. The human ANGPTL4 or chimeric ANGPTL4 protein expressed in the non-human animal can maintain the function of one or more wild-type or human ANGPTL4 proteins. In some embodiments, the genetically modified non-human animal does not express endogenous ANGPTL4 protein. In some embodiments, the endogenous ANGPTL4 protein of the genetically modified non-human animal is expressed at a reduced level compared to the ANGPTL4 protein in the wild-type animal. The "endogenous ANGPTL4 protein" described in this application refers to the ANGPTL4 protein encoded by the endogenous ANGPTL4 nucleotide sequence of the non-human animal (e.g., mouse) before genetic modification.

[0061] In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence encoding an amino acid that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence of human ANGPTL4 protein (NP_647475.1; SEQ ID NO: 2 or SEQ ID NO: 2 positions 31-406). In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence of SEQ ID NO: 5, 13, 16 or 21.

[0062] In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region in the non-human animal genome is replaced by the nucleotide sequence encoding the corresponding region of human ANGPTL4. In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region comprises all or part of the nucleotide sequence from the 5'UTR upstream nucleotide to the 3'UTR downstream nucleotide of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, the nucleotide sequence from the 5'UTR upstream nucleotide to the 3'UTR downstream nucleotide of the endogenous ANGPTL4 gene of the non-human animal comprises the nucleotide sequence from the 5'UTR upstream nucleotide to the 3'UTR downstream nucleotide of the endogenous ANGPTL4 gene of the non-human animal, exon 1 (including 5'UTR), intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6, exon 7 (including 3'UTR) and / or the nucleotide sequence downstream of 3'UTR of the endogenous ANGPTL4 gene of the non-human animal is replaced.

[0063] In some embodiments, the replaced nucleotide sequence encoding the endogenous ANGPTL4 region comprises a portion of exon 1, all of exons 2-6, and a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal; or, comprises a portion of exon 1 to a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal.

[0064] In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region is located in the endogenous or human ANGPTL4 regulatory region of the endogenous ANGPTL4 locus of a non-human animal. In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region is located within the nucleotide sequence upstream of the 5'UTR of the endogenous ANGPTL4 gene of a non-human animal to the nucleotide region downstream of the 3'UTR. In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region is located from a portion of exon 1 to a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal.

[0065] In some embodiments, the nucleotide sequence encoding the corresponding region of human ANGPTL4 is located at nucleotide sequence 168-1388 or 1-1872 of human ANGPTL4 gene transcript NM_139314.3.

[0066] In some embodiments, one or more cells of the genetically modified non-human animal express a human or chimeric ANGPTL4 protein (e.g., a humanized ANGPTL4 protein). In some embodiments, the human or chimeric ANGPTL4 protein comprises at least 50, 60, 70, 80, 90, 100, 200, 300, 350, 370, 375, 376, 377, 400, 401, 402, 403, 404, 405, or 406 consecutive amino acids identical to SEQ ID NO: 2 or the amino acid sequence set forth in SEQ ID NO: 2 at positions 31-406.

[0067] In some embodiments, the genome of the genetically modified non-human animal comprises all or part of the nucleotide sequence from the upstream 5'UTR to the downstream 3'UTR of the human ANGPTL4 gene. In some embodiments, the nucleotide sequence from the upstream 5'UTR to the downstream 3'UTR of the human ANGPTL4 gene comprises the nucleotide sequence from the upstream 5'UTR to the downstream 3'UTR of the human ANGPTL4 gene, the 5'UTR, the coding region sequence of the human ANGPTL4 gene, the 3'UTR and / or the nucleotide sequence from the downstream 3'UTR.

[0068] In some embodiments, the portion of the human ANGPTL4 gene from the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence comprises at least 5, 10, 100, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 10200, 10216, 11000, 12000, 13000, 14000, 15000, 15216, 15500, 15700 or 15793 bp of continuous nucleotide sequence.

[0069] In some embodiments, the genome of the genetically modified non-human animal comprises a portion of exon 1, all of exons 2-6, and a portion of exon 7 of the human ANGPTL4 gene, or a portion of exon 1 to exon 7 of the human ANGPTL4 gene.

[0070] In some embodiments, the portion from exon 1 to exon 7 of the human ANGPTL4 gene comprises at least 5, 10, 100, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 9500, 9565, 10000, 10200 or 10216 bp of continuous nucleotide sequence.

[0071] In some embodiments, the genome of the genetically modified non-human animal comprises all or part of a nucleotide sequence encoding a human ANGPTL4 protein. In some embodiments, the genome of the genetically modified non-human animal comprises all or part of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 of a human ANGPTL4 gene. In some embodiments, the genome of the genetically modified non-human animal comprises all or part of a nucleotide sequence as shown in SEQ ID NO: 5 or 16.

[0072] In some embodiments, the modified ANGPTL4 gene in the genome of the genetically modified non-human animal is heterozygous or homozygous for the endogenous modified (preferably replaced) locus.

[0073] In some embodiments, the humanized ANGPTL4 gene comprises a 5'UTR of a human ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 gene comprises a 5'UTR endogenous to a non-human animal (e.g., mouse). In some embodiments, the humanized ANGPTL4 gene comprises a 3'UTR endogenous to a non-human animal (e.g., mouse). In appropriate cases, based on sequence similarity, it can be reasonably inferred that non-human animal (e.g., mouse) and human ANGPTL4 genes are similarly regulated. As described herein, a humanized ANGPTL4 mouse comprises a replacement of an endogenous mouse locus that retains or does not retain mouse endogenous regulatory elements but comprises a human or humanized ANGPTL4 coding sequence. Expression of ANGPTL4 in a genetically modified heterozygous or homozygous mouse is completely normal.

[0074] In some embodiments, the present invention provides a genetically modified non-human animal, the genome of which comprises a deletion of an endogenous ANGPTL4 gene. In some embodiments, the deletion of the endogenous ANGPTL4 gene of the non-human animal comprises the entire nucleotide sequence upstream of the 5'UTR of the non-human animal ANGPTL4 gene, exon 1 (including the 5'UTR), exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 (including the 3'UTR) and / or the nucleotide sequence downstream of the 3'UTR of the non-human animal ANGPTL4 gene, or a partial deletion thereof.

[0075] In some embodiments, the deletion of the endogenous ANGPTL4 gene of the non-human animal comprises part of exon 1, all of exons 2-6, and part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, part of exon 1 to part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal is deleted.

[0076] In some embodiments, the deletion of the endogenous ANGPTL4 gene of the non-human animal further comprises one or more introns or portions of introns, wherein the introns are selected from one or more introns of intron 1, intron 2, intron 3, intron 4, intron 5 and / or intron 6 of the non-human animal ANGPTL4 gene.

[0077] In some embodiments, the deletion comprises at least 1 bp to at least 11511 bp of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, the deletion comprises at least 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1210, 1220, 1233, 1231, 1232, 1233, 1500, 1800, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1920, 1921, 1922, 1923, 1924, 1925, 1926, 1927, 1928, 1929, 1930, 1931, 1932, 1933, 1934, 1935, 1936, 1937, 1938, 1939, 1940, 1941, 1942, 1943, 1944, 1945 03, 1910, 1912, 1914, 1915, 1916, 2000, 3000, 4000, 5000, 6000, 6500, 6676, 7000, 8000, 9000, 9565, 10000, 11000, 11419, 11500, 11510 or 11511 bp of continuous nucleotide sequence or more.

[0078] In some embodiments, the deletion comprises at least 50 bp to at least 1916 bp of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7, such as 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1221, 1300, 1400, 1500, 1600, 1700, 1800, 1900 or 1916 bp of continuous nucleotide sequence or more (e.g., all of exons 1-7, or, at least 10 bp of continuous nucleotide sequence of exon 1 to at least 10 bp of continuous nucleotide sequence of exon 7).

[0079] The present invention provides a humanized mouse ANGPTL4 genomic DNA sequence, a construct expressing the amino acid sequence of the humanized ANGPTL4 protein, a cell comprising the construct, and a tissue or organ comprising the cell.

[0080] Therefore, in some embodiments, the present invention provides a chimeric (e.g., humanized) ANGPTL4 nucleotide sequence and / or amino acid sequence. In some embodiments, the chimeric (e.g., humanized) ANGPTL4 nucleotide sequence or amino acid sequence is homologous to an endogenous non-human animal ANGPTL4 mRNA (e.g., NM_020581.2), a non-human animal ANGPTL4 amino acid sequence (e.g., NP_065606.2, SEQ ID NO: 1), or a portion thereof (e.g., a portion of exon 1 and a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal; or, a nucleotide sequence from upstream of the 5'UTR to downstream of the 3'UTR of an endogenous ANGPTL4 gene of a non-human animal) having a sequence identity or identity of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. In some embodiments, the chimeric (e.g., humanized) ANGPTL4 nucleotide sequence or amino acid sequence is identical to a human ANGPTL4 mRNA sequence (e.g., NM_139314.3), a human ANGPTL4 amino acid sequence (e.g., NP_647475.1, SEQ ID NO: 2), or a portion thereof (e.g., a portion of exon 1, all of exons 2-6, and a portion of exon 7 of a human ANGPTL4 gene; or, a nucleotide sequence from upstream of the 5'UTR to downstream of the 3'UTR of a human ANGPTL4 gene) having a sequence identity or identity of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

[0081] In some embodiments, the nucleotide sequence encoding mouse ANGPTL4 (SEQ ID NO: 1 or positions 24-410 of SEQ ID NO: 1) is replaced with the corresponding nucleotide sequence encoding human ANGPTL4 (SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2).

[0082] In some embodiments, the human ANGPTL4 nucleotide sequence is operably linked to a regulatory element, such as a human or non-human animal ANGPTL4 promoter, an inducible promoter, an enhancer and / or a human or non-human animal regulatory element.

[0083] In some embodiments, at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, for example, a continuous or non-contiguous nucleotide sequence) of the chimeric nucleotide sequence of the present invention is different from all or part of the non-human animal ANGPTL4 nucleotide sequence (e.g., part of exon 1 to part of exon 7 of the non-human animal ANGPTL4 gene transcript NM_020581.2; or, all of exons 1-7 of the non-human animal ANGPTL4 gene transcript NM_020581.2).

[0084] In some embodiments, at least a portion of the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., a continuous or non-contiguous nucleotide sequence) is identical to all or part of a non-human animal ANGPTL4 nucleotide sequence (e.g., a portion of exon 1 and / or a portion of exon 7 of the non-human animal ANGPTL4 gene transcript NM_020581.2).

[0085] In some embodiments, at least a portion of the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides, e.g., a contiguous or non-contiguous nucleotide sequence) is different from all or a portion of a human ANGPTL4 nucleotide sequence (e.g., a portion of exon 1 and a portion of exon 7 of the human ANGPTL4 gene transcript NM_139314.3).

[0086] In some embodiments, at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, for example, a continuous or non-contiguous nucleotide sequence) of the chimeric nucleotide sequence is identical to all or part of a human ANGPTL4 nucleotide sequence (e.g., all of exons 1-7 of human ANGPTL4 gene transcript NM_139314.3; or, a portion of exon 1 to a portion of exon 7 of human ANGPTL4 gene transcript NM_139314.3).

[0087] In some embodiments, at least a portion of the amino acids encoded by the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, such as contiguous or non-contiguous amino acid residues) is different from all or part of the amino acid sequence of the non-human animal ANGPTL4 protein (e.g., amino acids 1-410 of the non-human animal ANGPTL4 protein sequence NP_065606.2 (SEQ ID NO: 1) or amino acids 24-410 of SEQ ID NO: 1).

[0088] In some embodiments, at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues, e.g., contiguous or non-contiguous amino acid residues) of the amino acid sequence encoded by the chimeric nucleotide sequence is identical to all or part of the amino acid sequence of a human ANGPTL4 protein (e.g., amino acids 1-406 of the human ANGPTL4 protein sequence NP_647475.1 (SEQ ID NO: 2) or amino acids 31-406 of SEQ ID NO: 2).

[0089] The present invention also provides a humanized ANGPTL4 amino acid sequence, wherein the humanized ANGPTL4 amino acid sequence comprises any one of the following groups:

[0090] A) the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406;

[0091] B) is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to SEQ ID NO:2 or the amino acid sequence set forth in positions 31-406 of SEQ ID NO:2;

[0092] C) an amino acid sequence encoded by a nucleic acid sequence, wherein the nucleic acid sequence is capable of hybridizing under low stringency conditions or stringent conditions with a nucleotide sequence encoding the amino acids set forth in SEQ ID NO: 2 or SEQ ID NO: 2 at positions 31 to 406;

[0093] D) differs from SEQ ID NO:2 or the amino acid sequence set forth in positions 31-406 of SEQ ID NO:2 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or no more than 1 amino acid; or

[0094] E) an amino acid sequence comprising a substitution, deletion and / or insertion of one or more amino acid residues as shown in SEQ ID NO: 2 or SEQ ID NO: 2 at positions 31-406.

[0095] The present invention also provides a humanized ANGPTL4 nucleotide (eg, DNA or RNA) sequence, wherein the humanized ANGPTL4 nucleotide sequence comprises any one of the following groups:

[0096] A) a nucleotide sequence as shown in SEQ ID NO: 5, 13, 16 or 21, or a nucleotide sequence encoding a homologous amino acid sequence of a humanized ANGPTL4 protein;

[0097] B) a nucleotide sequence that can hybridize to the nucleotide sequence shown in SEQ ID NO: 5, 13, 16 or 21 under low stringency conditions or stringent conditions;

[0098] C) a nucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO: 5, 13, 16 or 21;

[0099] D) the amino acid sequence encoded by it is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to the amino acid sequence encoded by SEQ ID NO: 5, 13, 16 or 21;

[0100] E) encodes an amino acid sequence that differs from the amino acid sequence encoded by SEQ ID NO: 5, 13, 16 or 21 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or no more than 1 amino acid; or

[0101] F) The amino acid sequence encoded by the amino acid sequence is the same as that shown in the amino acid sequence encoded by SEQ ID NO: 5, 13, 16 or 21, including an amino acid sequence in which one or more amino acid residues are replaced, deleted and / or inserted.

[0102] The present invention further provides a humanized mouse ANGPTL4 genomic DNA sequence, which is obtained by reverse transcription of mRNA transcribed from the genomic DNA sequence and is consistent with or complementary to a DNA sequence homologous to the sequence shown in SEQ ID NO: 5, 13, 16 or 21.

[0103] In order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are compared for the purpose of optimal comparison (e.g., for optimal comparison, gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences, and non-homologous sequences can be ignored for the purpose of comparison). The amino acid residues or nucleotides on the corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, which needs to be introduced to achieve the optimal comparison of the two sequences, taking into account the number of gaps and the length of each gap. For example, the comparison of the sequences and the determination of the percent identity between the two sequences can be completed using the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0104] The percentage (homology percentage) of conservative residues with similar physicochemical properties, such as leucine and isoleucine, can also be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage.

[0105] The present invention also provides cells, tissues and non-human animals (e.g., mice) comprising the nucleotide sequences of the present invention, as well as cells, tissues and animals (e.g., mice) expressing human or chimeric (e.g., humanized) ANGPTL4 at the endogenous ANGPTL4 locus of the non-human animal.

[0106] Genetically modified non-human animals

[0107] The "genetically modified non-human animal" or "genetically modified non-human animal" described in the present invention refers to a non-human animal in which at least one chromosome in the genome of the non-human animal has exogenous DNA (e.g., human ANGPTL4). In some embodiments, at least one or more cells, for example, at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40% or 50% of the cells in the genetically modified non-human animal have exogenous DNA. The cells with exogenous DNA can be various cells, for example, somatic cells, immune cells (e.g., T cells, B cells, NK cells, antigen presenting cells, macrophages, dendritic cells), germ cells, blastocysts or tumor cells. In some embodiments, a genetically modified non-human animal is provided, the non-human animal comprising a modified endogenous ANGPTL4 locus, comprising an exogenous sequence (e.g., a human sequence), for example, replacing one or more non-human sequences with one or more human sequences, or inserting one or more human and / or non-human sequences. Non-human animals are generally able to pass genetic modifications to offspring through germline transmission.

[0108] The "chimeric (x) gene" or "chimeric (x) nucleic acid" of the present invention refers to a gene or nucleic acid, wherein two or more parts of the gene or nucleic acid are from different species, or at least one sequence of the gene or nucleic acid is different from the nucleic acid in a wild-type animal. In some embodiments, a chimeric (x) gene or a chimeric (x) nucleic acid has at least a portion of a sequence having two or more different species sources, for example, sequences encoding different proteins or sequences encoding the same (or homologous) proteins of two or more different species. In some embodiments, a chimeric (x) gene or a chimeric (x) nucleic acid refers to a humanized (x) gene or a humanized (x) nucleic acid.

[0109] The "chimeric (x) protein" or "chimeric (x) polypeptide" of the present invention refers to a protein or polypeptide, wherein two or more parts of the polypeptide or protein are from different species, or at least one sequence of the protein or polypeptide is different from the amino acid sequence in a wild-type animal. In some embodiments, at least a portion of the sequence of the chimeric (x) protein or chimeric (x) polypeptide has two or more different species sources, for example, the same (or homologous) proteins of different species. In some embodiments, the chimeric (x) protein or chimeric (x) polypeptide refers to a humanized (x) protein or humanized (x) polypeptide.

[0110] The "humanized (x) protein" or "humanized (x) polypeptide" of the present invention refers to a protein or polypeptide, wherein at least a portion of the protein or polypeptide is derived from a human (x) protein or human (x) polypeptide. In some embodiments, the humanized (x) protein or humanized (x) polypeptide refers to a human (x) protein or human (x) polypeptide.

[0111] The "humanized (x) nucleic acid" or "humanized (x) gene" of the present invention refers to a nucleic acid, wherein at least a portion of the nucleic acid is from a human. In some embodiments, the nucleic acids in the humanized (x) nucleic acid or humanized (x) gene are all derived from humans. In some embodiments, the humanized (x) nucleic acid or humanized (x) gene refers to a humanized exon, and the humanized exon can be a human exon or a chimeric exon. In some embodiments, the humanized (x) nucleic acid or humanized (x) gene refers to a humanized exon and a humanized intron, and the humanized intron can be a human intron or a chimeric intron.

[0112] In some embodiments, the chimeric (x) gene or chimeric (x) nucleic acid is a humanized ANGPTL4 gene or humanized ANGPTL4 nucleic acid. In some embodiments, at least a portion of the humanized ANGPTL4 gene or humanized ANGPTL4 nucleic acid is derived from a human ANGPTL4 gene, and at least a portion of the humanized ANGPTL4 gene or humanized ANGPTL4 nucleic acid is derived from a non-human animal ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 gene or humanized ANGPTL4 nucleic acid comprises a sequence encoding an ANGPTL4 protein. In some embodiments, the encoded ANGPTL4 protein has at least one activity of a human ANGPTL4 protein and / or a non-human animal ANGPTL4 protein.

[0113] In some embodiments, the chimeric (x) protein or chimeric (x) polypeptide is a humanized ANGPTL4 protein or a humanized ANGPTL4 polypeptide. In some embodiments, at least one or more portions of the amino acid sequence of the humanized ANGPTL4 protein or humanized ANGPTL4 polypeptide are from a human ANGPTL4 protein. In some embodiments, at least one or more portions of the amino acid sequence of the humanized ANGPTL4 protein or humanized ANGPTL4 polypeptide are from a non-human animal ANGPTL4 protein. In some embodiments, the humanized ANGPTL4 protein or humanized ANGPTL4 polypeptide is functional, or has at least one activity of a human ANGPTL4 protein and / or a non-human animal ANGPTL4 protein.

[0114] The non-human animal of genetic modification can be various animals, for example, rodents (such as mice, rats), rabbits, pigs, cattle (such as, cattle, bulls, buffalo), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (such as, marmosets, rhesus monkeys). For the non-human animals that are not easy to obtain suitable genetically modified embryonic stem cells (ES), alternative methods are used to construct non-human animals comprising genetic modification. Such methods include, for example, modifying non-ES cell genomes (such as, fibroblasts or induced pluripotent stem cells) and using nuclear transplantation to transfer the modified genome to suitable cells, such as oocytes, and incubating modified cells (such as, modified oocytes) in non-human animals under appropriate conditions to form embryos. The above-mentioned construction method is known in the art, and is described in "A.Nagy, et al., "Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition), " Cold Spring Harbor Laboratory Press, 2006 ", the entire contents of which are incorporated herein by reference.

[0115] In one aspect, the non-human animal is a mammal. In some embodiments, the genetically modified non-human animal is a rodent. Rodents can be selected from mice, rats and hamsters. In one embodiment, the rodent is selected from the family Muridae. In one embodiment, the genetically modified non-human animal is from a family selected from the family Cricetidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muroidea (true mice and rats, gerbils, spiny mice, crested rats), Malboridae (climbing mice, rock mice, tailed rats, Madagascar rats and mice), Spiny Dormouse (e.g., spiny dormouse) and Muridae (e.g., mole rats, bamboo rats and zokors). In a specific embodiment, the genetically modified rodent is selected from true mice or rats (Muroidea), gerbils, spiny mice and crested rats. In one embodiment, the genetically modified non-human animal is from a member of the Muridae family. In one embodiment, the non-human animal is a rodent. In a specific embodiment, the rodent is selected from mice and rats. In one embodiment, the non-human animal is a mouse.

[0116] In some embodiments, the non-human animal can be an immunodeficient non-human mammal. For example, an immunodeficient rodent, an immunodeficient rabbit, an immunodeficient pig, an immunodeficient monkey, etc. In some embodiments, the non-human animal is a mouse of the C57BL strain, and the C57BL strain is selected from C57BL / a, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL6, C57BL / 10, C57BL10ScSn, C57BL / 10Cr and C57BL / Ola. In some embodiments, the mouse is a 129 strain selected from 129 / J, 129 / ReJ, 129 / OlaHsd, 129 / Sv, 129 / SvJ, 129 / Re, 129 / RrJ, 129 / Sv-ter / +. These mice are described in, for example, Festing et al., Revised nomenclature for strain 129 mice, Mammalian Genome 10: 836 (1999); Auerbach et al., Establishment and Chimera Analysis of 129 / SvEv-and C57BL / 6-Derived Mouse Embryonic Stem Cell Lines (2000), the relevant contents of which are incorporated herein by reference in their entirety. In some embodiments, the genetically modified mouse is a hybrid of the 129 strain and the C57BL / 6 strain. In some embodiments, the mouse is a hybrid of the 129 strain, or a hybrid of the BL / 6 strain. In some embodiments, the mouse is a BALB strain, such as a BALB / c strain. In some embodiments, the mouse is a hybrid of a BALB strain and another strain. In some embodiments, the mouse is from a hybrid line (e.g., 50% BALB / c-50% 12954 / Sv; or 50% C57BL / 6-50% 129). In certain embodiments, the non-human animal is a rodent. In certain embodiments, the non-human animal is a mouse with BALB / c, BALB / cHeAn, BALB / cJ, BALB / cR1, BALB / cWt, C57BL / 10, C57BL / 10ScSn, C57BL (C57BL / 10Cr and C57BL / Ola), C58, CBA / Br, CBA / Ca, CBA / J, CBA / st or CBA / H strains. In certain embodiments, the non-human animal is a rat. The rat can be selected from Wistar rats, LEA strains, Sprague-Dawley strains, Fischer strains, F344, F6 and Dark Agouti.In some embodiments, the rat strain is a hybrid of two or more strains selected from Wistar, LEA, Sprague-Dawley, Fischer, F344, F6, and Dark Agouti.

[0117] The genetically modified non-human animal includes a modification of an endogenous ANGPTL4 gene site (or locus) of the non-human animal. In some embodiments, the modification comprises a nucleotide sequence encoding at least a portion of a mature ANGPTL4 protein (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identity to a mature ANGPTL4 protein amino acid sequence). The present invention provides cells (e.g., ES cells, somatic cells) that may include the genetic modifications described herein. In some embodiments, the genetically modified non-human animal includes a modification of an endogenous ANGPTL4 gene site of the non-human animal.

[0118] The genetically modified non-human animal can express human ANGPTL4 and / or chimeric (e.g., humanized) ANGPTL4 at an endogenous locus of the non-human animal, wherein the endogenous ANGPTL4 gene of the non-human animal (e.g., mouse) has been replaced (substituted) or inserted with a human ANGPTL4 gene and / or a nucleotide sequence encoding human ANGPTL4 or a nucleotide sequence having at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to human ANGPTL4. In some embodiments, the endogenous ANGPTL4 locus of the non-human animal is modified by comprising all or part of a nucleotide sequence encoding a mature human ANGPTL4 protein.

[0119] In some embodiments, the genetically modified non-human animal (e.g., mouse) can express human ANGPTL4 and / or chimeric ANGPTL4 (e.g., humanized ANGPTL4) under the control of endogenous or human regulatory elements (e.g., 5'UTR, 3'UTR, promoter or enhancer) of the non-human animal. Insertion or substitution at the endogenous locus of the non-human animal provides a non-human animal that expresses human ANGPTL4 or chimeric ANGPTL4 (e.g., humanized ANGPTL4) in a suitable cell without causing potential pathology observed in some other transgenic non-human animals known in the art. The human ANGPTL4 or chimeric ANGPTL4 (e.g., humanized ANGPTL4) expressed in the non-human animal can maintain one or more functions of wild-type animal ANGPTL4 or human ANGPTL4 in the non-human animal. In some embodiments, the genetically modified non-human animal does not express endogenous ANGPTL4. In some embodiments, the expression level of endogenous ANGPTL4 in the genetically modified non-human animal is reduced compared to the expression level of ANGPTL4 in the wild-type animal. As used herein, the term "endogenous ANGPTL4" refers to the ANGPTL4 protein expressed by the endogenous ANGPTL4 nucleotide sequence of a non-human animal (eg, mouse) before any genetic modification.

[0120] In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence encoding a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence of human ANGPTL4 (NP_647475.1; SEQ ID NO: 2 or SEQ ID NO: 2 positions 31-406). In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 5, 13, 16 or 21. In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to positions 168-1388 or positions 1-1872 of NM_139314.3.

[0121] In some embodiments, the genome of the genetically modified non-human animal includes: all or part of exon 1, exon 2, exon 3, exon 4, exon 5, exon 6 and / or exon 7 of the human ANGPTL4 gene (preferably also including 5'UTR upstream nucleotide sequence and / or 3'UTR downstream nucleotide sequence); and / or, a nucleotide sequence encoding all or part of the amino acid sequence of human ANGPTL4; and / or, a nucleotide sequence encoding SEQ ID NO: 2 or SEQ ID NO: 2 positions 31-406.

[0122] In some embodiments, the genome of the genetically modified non-human animal includes part of exon 1, all of exons 2-6, and part of exon 7 of the human ANGPTL4 gene; or includes part of exon 1 to part of exon 7. In some embodiments, the part of exon 1 of the human ANGPTL4 gene contains at least 50-485 bp, such as 50, 60, 70, 80, 90, 100, 200, 300, 310, 312, 314, 316, 318, 400, 440, 460, 480, 482, 484 or 485 bp of continuous nucleotide sequence. In some embodiments, the part of exon 1 of the human ANGPTL4 gene contains the nucleotide sequence of the coding region. In some embodiments, the portion of human ANGPTL4 gene exon 7 comprises at least 50-666 bp of continuous nucleotide sequence, such as 50, 60, 70, 80, 90, 100, 140, 160, 180, 181, 182, 200, 300, 400, 500, 600, 620, 640, 660, 662, 664 or 666 bp of continuous nucleotide sequence. In some embodiments, the portion of human ANGPTL4 gene exon 7 comprises the nucleotide sequence of the coding region.

[0123] In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence upstream of the 5'UTR of the human ANGPTL4 gene, all of exons 1-7, and a nucleotide sequence downstream of the 3'UTR. In some embodiments, the nucleotide sequence upstream of the 5'UTR of the human ANGPTL4 gene comprises at least 50-8000 bp, such as 50, 100, 200, 500, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 7000 or 8000 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence upstream of the 5'UTR of the human ANGPTL4 gene comprises a nucleotide sequence of 100-500 bp, 1000-3000 bp or 5000-8000 bp. In some embodiments, the nucleotide sequence downstream of the 3'UTR of the human ANGPTL4 gene comprises at least 50-1000 bp, such as 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 520, 540, 560, 570, 574, 577, 600, 800, 900 or 1000 bp of continuous nucleotide sequence. In some embodiments, the nucleotide sequence downstream of the 3'UTR of the human ANGPTL4 gene comprises 400-700 bp.

[0124] In some embodiments, the genome of the genetically modified non-human animal includes a portion of exon 1 and a portion of exon 7 of an endogenous ANGPTL4 gene of the non-human animal (e.g., mouse ANGPTL4). In some embodiments, the portion of exon 1 of the endogenous ANGPTL4 gene of the non-human animal comprises at least 50-513 bp of continuous nucleotide sequence, such as 50, 60, 70, 80, 90, 100, 150, 160, 180, 182, 183, 200, 300, 310, 320, 330, 400, 500, 510, 511, 512 or 513 bp of nucleotides. In some embodiments, the portion of exon 1 includes a 5'UTR. In some embodiments, the portion of exon 7 comprises at least 50-669 bp of continuous nucleotide sequence, such as 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 181, 182, 200, 300, 400, 480, 487, 488, 489, 490, 500, 600, 620, 640, 660 or 669 bp of nucleotides. In some embodiments, the portion of exon 7 includes a 3'UTR.

[0125] In some embodiments, the non-human animal has a nucleotide sequence encoding a chimeric human / non-human ANGPTL4 polypeptide at an endogenous ANGPTL4 locus, and the non-human animal expresses functional ANGPTL4 on the surface of its cells. In some embodiments, the human portion of the chimeric human / non-human ANGPTL4 polypeptide may comprise an amino acid sequence encoded by a portion of exon 1, all of exons 2-6, and a portion of exon 7 of a human ANGPTL4 gene. In some embodiments, the human portion of the chimeric human / non-human ANGPTL4 polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406.

[0126] In some embodiments, the modified gene in the genome of the genetically modified non-human animal is homozygous or heterozygous for the endogenous replaced locus. In some embodiments, the modified ANGPTL4 gene in the genome of the genetically modified non-human animal is homozygous or heterozygous for the endogenous replaced locus.

[0127] In some embodiments, the humanized ANGPTL4 gene comprises the 5'UTR of the human ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 gene comprises the 5'UTR of the non-human animal endogenous (e.g., mouse) ANGPTL4 gene. In some embodiments, the humanized ANGPTL4 gene comprises the 3'UTR of the human ANGPTL4 gene. In some embodiments, the humanization comprises the 3'UTR of the non-human animal endogenous (e.g., mouse) ANGPTL4 gene. Where appropriate, it is reasonable to assume that, based on the similarity of the non-human animal and human ANGPTL4 gene sequences, they may be similarly regulated. As shown in the present application, a humanized ANGPTL4 mouse comprising an insertion or replacement in the mouse endogenous ANGPTL4 locus, which retains the mouse regulatory elements but comprises the human ANGPTL4 coding sequence, does not exhibit pathological phenomena. The expression of ANGPTL4 in the genetically modified heterozygous or homozygous mice is normal.

[0128] In some embodiments, the present invention also provides a genetically modified non-human animal, whose genome comprises a disruption (deletion) of an endogenous ANGPTL4 gene of a non-human animal. In some embodiments, the disruption (deletion) of the endogenous ANGPTL4 gene comprises a deletion of a nucleotide sequence upstream of the 5'UTR, exon 1, exon 2, exon 3, exon 4, exon 5, exon 6, exon 7 and / or a nucleotide sequence downstream of the 3'UTR, or a partial deletion thereof.

[0129] In some embodiments, the disruption of the endogenous ANGPTL4 gene in the non-human animal further comprises a deletion selected from intron 1, intron 2, intron 3, intron 4, intron 5 and / or intron 6.

[0130] In some embodiments, the deletion of the endogenous ANGPTL4 gene of a non-human animal comprises a portion of exon 1, all of exons 2-6, and a portion of exon 7. In some embodiments, the portion of exon 1 of the endogenous ANGPTL4 gene of a non-human animal comprises at least 50, 60, 70, 80, 90, 100, 150, 160, 180, 182, 183, 200, 300, 310, 320, 330, 400, 500, 510, 511, 512, or 513 bp of consecutive nucleotides. In some embodiments, the deleted portion of exon 1 of the endogenous ANGPTL4 gene of a non-human animal comprises the nucleotide sequence of the coding region. In some embodiments, the portion of exon 7 of the non-human animal endogenous ANGPTL4 gene deleted comprises at least 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 181, 182, 200, 300, 500, 600, 620, 640, 660 or 669 bp of consecutive nucleotides. In some embodiments, the portion of exon 7 of the non-human animal endogenous ANGPTL4 gene deleted comprises the nucleotide sequence of the coding region.

[0131] In some embodiments, the deletion of the endogenous ANGPTL4 gene of a non-human animal comprises a 5'UTR upstream nucleotide sequence, all of exons 1-7, and a 3'UTR downstream nucleotide sequence. In some embodiments, the 5'UTR upstream nucleotide sequence of the endogenous ANGPTL4 gene of a non-human animal comprises at least 50-6000 bp, such as 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 3000, 4000, 4400, 4600, 4700, 4720, 4740, 4743, 4800, 4900, 5000, 5500 or 6000 bp of continuous nucleotides. In some embodiments, the 5'UTR upstream nucleotide sequence of the non-human animal ANGPTL4 gene comprises 100-500bp, 1000-2000bp or 3000-5000bp of continuous nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the non-human animal ANGPTL4 gene comprises at least 5-300bp, such as 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 100, 200 or 300bp of continuous nucleotides. In some embodiments, the 3'UTR downstream nucleotide sequence of the non-human animal ANGPTL4 gene comprises 50-100bp of continuous nucleotides.

[0132] In some embodiments, the deletion comprises at least 1 bp to at least 11511 bp of the endogenous ANGPTL4 gene of the non-human animal. In some embodiments, the deletion comprises at least 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1210, 1220, 1233, 1231, 1232, 1233, 1500, 1800, 1900, 1901, 1902 , 1903, 1910, 1912, 1914, 1915, 1916, 2000, 3000, 4000, 5000, 6000, 6500, 6676, 7000, 8000, 9000, 10000, 11000, 11419, 11500, 11510 or 11511 bp of continuous nucleotide sequence or more.

[0133] The present invention further relates to the ANGPTL4 genomic DNA sequence of humanized mice, a DNA sequence obtained by reverse transcription of mRNA that is identical to or complementary to the DNA sequence; a construct expressing the amino acid sequence thereof; a cell comprising the construct thereof; and a tissue or organ comprising the cell thereof.

[0134] The present invention further relates to a non-human mammal produced by the above method. In some embodiments, its genome comprises the above humanized ANGPTL4 gene.

[0135] In some embodiments, the non-human mammal is a rodent. In some embodiments, the non-human mammal is a mouse.

[0136] In some embodiments, the non-human mammal expresses a protein encoded by a humanized ANGPTL4 gene.

[0137] In addition, the present invention also provides a non-human mammal model carrying a tumor, wherein the non-human mammal model is obtained by the method described in the present application. In some embodiments, the non-human mammal is a rodent (eg, mouse).

[0138] The present invention also provides a cell or cell line derived from a non-human mammal or its offspring, or a non-human mammal carrying a tumor, or a primary cell culture, which is derived from a non-human mammal or its offspring, or a non-human mammal carrying a tumor, or a tissue, organ, or culture thereof derived from a non-human mammal or its offspring. When it carries a tumor, it is derived from a tumor tissue of a non-human mammal or its offspring, or a non-human mammal carrying a tumor.

[0139] The present invention provides a non-human mammal produced by any of the methods described herein. In some embodiments, a non-human mammal, a genetically modified non-human animal, wherein the genome of the genetically modified non-human animal comprises DNA of human or humanized ANGPTL4 is provided.

[0140] In some embodiments, a non-human mammal comprises a gene construct described herein (e.g., Figure 2 , Figure 6 , Figure 7 , Fig.10 In some embodiments, a non-human mammal expressing a human or humanized ANGPTL4 protein is provided. In some embodiments, a cell, tissue or organ specifically expressing a human or humanized ANGPTL4 protein is provided.

[0141] In some embodiments, the expression of human or humanized ANGPTL4 protein in non-human animals is controllable, such as by adding specific inducers or repressors. In some embodiments, the specific inducer is selected from the tetracycline system (Tet-Off System / Tet-On System) or the tamoxifen system (Tamoxifen System).

[0142] The non-human mammal can be any non-human animal known in the art that can be used in the methods described herein. In some embodiments, the non-human mammal is a mammal (e.g., a rodent). In some embodiments, the non-human mammal is a mouse.

[0143] The non-human mammals described above are subjected to genetic, molecular and behavioral analyses. The present invention provides offspring produced by mating with non-human mammals of the same genotype or other genotypes.

[0144] The present invention provides a cell line or primary cell culture derived from a non-human mammal or its descendants. For example, a cell culture-based model can be prepared by the following method. The cell culture can be obtained by isolation from a non-human mammal, or cells can be obtained from a cell culture established using the same construct and standard cell transfection techniques. The integration of a genetic construct comprising a DNA sequence encoding a human ANGPTL4 protein can be detected by a variety of methods.

[0145] There are many analytical methods that can be used to detect exogenous DNA, including nucleic acid level methods (including the use of reverse transcription-polymerase chain reaction (RT-PCR) or Southern Blot and in situ hybridization) and protein level methods (including histochemical analysis, immunoblot analysis and in vitro binding studies). In addition, the expression level of the target gene can be quantified by ELISA methods well known to those skilled in the art. Many standard analytical methods can be used to achieve quantitative detection. For example, RT-PCR and hybridization methods can be used to detect transcription levels, including RNase protection assays, Southern Blots, and RNA dot hybridization analysis (RNAdot). Immunohistochemical staining, flow cytometry, and Western blots can also be used to detect the presence of human or humanized ANGPTL4 protein.

[0146] In some embodiments, the genetically modified non-human animal described herein (eg, a mouse homozygous for humanized ANGPTL4 gene) can express human or humanized ANGPTL4 in one or more cells (eg, cells of liver tissue).

[0147] Carrier

[0148] The present invention provides a targeting vector targeting ANGPTL4, comprising: a) a DNA fragment (5' arm) homologous to the 5' end of the switch region to be changed, which is selected from the genomic DNA of the ANGPTL4 gene and has a length of 100 to 10,000 nucleotides; b) a desired donor sequence encoding a donor region (donor DNA sequence); and c) a DNA fragment (3' arm) homologous to the 3' end of the switch region to be changed, which is selected from the genomic DNA of the ANGPTL4 gene and has a length of 100 to 10,000 nucleotides.

[0149] In some embodiments, a) the DNA fragment homologous to the 5' end of the switch region to be altered is selected from a nucleotide sequence with at least 90% identity to NCBI Accession No. NC_000083.7; c) the DNA fragment homologous to the 3' end of the switch region to be altered is selected from a nucleotide sequence with at least 90% identity to NCBI Accession No. NC_000083.7.

[0150] In some embodiments, a) a DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence at positions 34000367 to 34004613 of NCBI Accession No. NC_000083.7; c) a DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence at positions 33989662 to 33993564 of NCBI Accession No. NC_000083.7.

[0151] In some embodiments, a) a DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence at positions 34000367 to 34002091 of NCBI Accession No. NC_000083.7; c) a DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence at positions 33993225 to 33994360 of NCBI Accession No. NC_000083.7.

[0152] In some embodiments, a) a DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence at positions 34005293 to 34009497 of NCBI Accession No. NC_000083.7; c) a DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence at positions 33989831 to 33993781 of NCBI Accession No. NC_000083.7.

[0153] In some embodiments, a) the DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence at positions 34005293 to 34006620 of NCBI Accession No. NC_000083.7; c) the DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence at positions 33992362 to 33993781 of NCBI Accession No. NC_000083.7.

[0154] In some embodiments, the length of the genomic nucleotide sequence selected for the targeting vector can exceed about 1 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 5.8 kb, 6.5 kb, 7 kb, 7.5 kb, 8 kb, 8.5 kb, 9 kb, 9.5 kb, 10 kb, 15 kb, 16 kb, 18 kb, 19 kb or 20 kb.

[0155] In some embodiments, the switch region to be changed is located on exon 1 to exon 7 of the non-human animal ANGPTL4 gene (e.g., positions 168-1388 of NM_139314.3). In some embodiments, the switch region to be changed is located on the nucleotide sequence upstream of the 5'UTR to the nucleotide sequence downstream of the 3'UTR of the non-human animal ANGPTL4 gene (4743 bp upstream of the 5'UTR to 92 bp downstream of the 3'UTR of the non-human animal ANGPTL4 gene). In some embodiments, the targeting vector further comprises one or more marker genes. For example, a resistance gene for positive clone screening or a gene encoding a negative selection marker. In some embodiments, the resistance gene for positive clone screening is the neomycin phosphotransferase coding sequence Neo. In some embodiments, the gene encoding the negative selection marker is the gene encoding the diphtheria toxin A subunit (DTA). In some embodiments, the targeting vector further comprises two Frt recombination sites arranged in the same direction on both sides of the resistance gene for positive clone screening.

[0156] In some embodiments, the 5' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 3, 10, 14 or 22; the 3' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 4, 11, 15 or 23.

[0157] In some embodiments, the 5' arm is a nucleotide with at least 90% identity to NCBI Accession No. NC_000083.7, and in some embodiments, the 5' arm sequence comprises the nucleotide sequence shown in SEQ ID NO: 3, 10, 14 or 22. In some embodiments, the 3' arm is a nucleotide with at least 90% identity to NCBI Accession No. NC_000083.7, and in some embodiments, the 3' arm sequence comprises the nucleotide sequence shown in SEQ ID NO: 4, 11, 15 or 23.

[0158] In some embodiments, the 5' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 3; the 3' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 4. In some embodiments, the 5' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 10; the 3' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 11. In some embodiments, the 5' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 14; the 3' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 15. In some embodiments, the 5' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 22; the 3' arm sequence is a nucleotide sequence as shown in SEQ ID NO: 23.

[0159] In some embodiments, the targeting vector comprises a human sequence (e.g., positions 8364322-8373886 of NC_000019.10, or positions 8359155-8374947 of NC_000019.10). For example, the human sequence in the targeting vector includes: a partial or complete nucleotide sequence of a human ANGPTL4 gene, preferably including a portion of exon 1, all of exons 2-6, and a portion of exon 7 of a human ANGPTL4 gene, or a portion of exon 1 to a portion of exon 7 of a human ANGPTL4 gene, or a 5'UTR upstream nucleotide sequence, all of exons 1-7, and a 3'UTR downstream nucleotide sequence of a human ANGPTL4 gene. In some embodiments, the human sequence in the targeting vector includes all or part of a nucleotide sequence encoding a human ANGPTL4 protein (SEQ ID NO: 2 or positions 31-406 of SEQ ID NO: 2).

[0160] In some embodiments, the targeting vector comprises, from the 5' end to the 3' end, a 5' arm, a 5'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, a nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and a 3'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR and a 3' arm.

[0161] In some embodiments, the targeting vector comprises, from the 5' end to the 3' end, a 5' arm, a portion of exon 1 to a portion of exon 7 of the human ANGPTL4 gene, and a 3' arm.

[0162] In some embodiments, the targeting vector comprises, from the 5' end to the 3' end:

[0163] A) SEQ ID NO: 3, 5, 4;

[0164] B) SEQ ID NO: 3, 16, 4;

[0165] C) SEQ ID NO: 10, 5, 11;

[0166] D) SEQ ID NO: 10, 16, 11;

[0167] E) SEQ ID NO: 14, 5, 15;

[0168] F) SEQ ID NO: 14, 16, 15;

[0169] G) SEQ ID NO: 22, 5, 23;

[0170] H) SEQ ID NO: 22, 16, 23;

[0171] In some embodiments, the targeting vector further comprises a Neo box, which can be inserted into the 5' arm, the 3' arm or the donor region.

[0172] In some embodiments, the targeting vector further comprises one or more of SEQ ID NO: 6, 7, 8, 9, 17, 18, 19 or 20.

[0173] The present invention also provides a vector for constructing a humanized animal model or a knockout model. In some embodiments, the vector comprises an sgRNA sequence, wherein the sgRNA sequence targets the ANGPTL4 gene, and the sgRNA is unique on the target sequence (target site) on the switch region to be changed, and satisfies the sequence arrangement rule of 5'-NNN(20)-NGG3' or 5'-CCN-N(20)-3'; and in some embodiments, the target site of the sgRNA on the non-human animal ANGPTL4 gene is located in exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4, exon 5, intron 5, exon 6, intron 6 or exon 7, or upstream of the 5'UTR of the mouse ANGPTL4 gene, or downstream of the 3'UTR.

[0174] In some embodiments, the targeting sequence (target site) is shown as SEQ ID NO: 34 and 35. Therefore, the present invention provides sgRNA sequences for constructing genetically modified animal models. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 36 and 38. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 40 and 42. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 37 and 39. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 41 and 43.

[0175] In some embodiments, the targeting sequence (target site) is shown as SEQ ID NO: 52 and 53. Therefore, the present invention provides sgRNA sequences for constructing genetically modified animal models. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 54 and 56. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 58 and 60. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 55 and 57. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 59 and 61.

[0176] In some embodiments, the present invention relates to a plasmid construct (sgRNA vector) (e.g., pT7-sgRNA) comprising an sgRNA sequence and / or a cell comprising the construct.

[0177] The present invention also relates to a cell comprising the targeting vector or the sgRNA or the sgRNA vector as described above.

[0178] In addition, the present invention also provides a non-human mammalian cell having any one of the above-mentioned targeting vectors or the above-mentioned sgRNA or the above-mentioned constructs (e.g., gene constructs or sgRNA vectors), and one or more in vitro transcripts of the constructs described in the present application. In some embodiments, the cell comprises Cas9 mRNA or its in vitro transcript.

[0179] In some embodiments, the cell is heterozygous for the gene. In some embodiments, the cell is homozygous for the gene.

[0180] In some embodiments, the non-human mammalian cell is a mouse cell. In some embodiments, the cell is a fertilized egg cell. In some embodiments, the cell is an embryonic stem cell. In some embodiments, the cell is any cell capable of expressing ANGPTL4.

[0181] The present invention also relates to the use of the above-mentioned targeting vector or the above-mentioned sgRNA or the above-mentioned sgRNA vector in ANGPTL4 gene modification.

[0182] Methods for constructing genetically modified non-human animals

[0183] Genetically modified non-human animals can be prepared by several gene editing techniques known in the art, including homologous recombination technology using embryonic stem cells, gene targeting technology, CRISPR / Cas9 technology, zinc finger nuclease technology, transcription activator-like effector nuclease technology, homing endonuclease or other molecular biology techniques. In some embodiments, homologous recombination technology is preferably used. In some embodiments, CRISPR / Cas9 gene editing technology can construct genetically modified non-human animals. In some embodiments, CRISPR-Cas9 genome editing is used to produce genetically modified non-human animals. Many of these genome editing technologies are known in the art and are described in "Delivery technologies for genome editing," Nature Reviews Drug Discovery 16.6 (2017): 387-399" by Yin et al., which is incorporated into this application by reference. The present invention also provides many other methods for genome editing, for example, microinjecting transgenic cells into enucleated oocytes and fusing the enucleated oocytes with another transgenic cell.

[0184] In some embodiments, the nucleotide sequence encoding the endogenous ANGPTL4 region in the endogenous genome of at least one cell of the non-human animal is replaced by the nucleotide sequence encoding the corresponding region of human ANGPTL4. In some embodiments, the expression level of the endogenous ANGPTL4 protein of the non-human animal is reduced or absent compared to the wild type. In some embodiments, the replacement occurs in cells such as germ cells, somatic cells, blastocysts or fibroblasts. The nucleus of a somatic cell or fibroblast can be inserted into an enucleated oocyte.

[0185] Figure 2 , Figure 6 , Figure 7 or Fig.10 A humanized targeting strategy for the mouse ANGPTL4 locus is shown. The targeting vector comprises a 5' homology arm, a human or humanized ANGPTL4 gene fragment, and a 3' homology arm. The process involves replacing the corresponding endogenous ANGPTL4 sequence of a non-human animal with a human or humanized ANGPTL4 sequence using homologous recombination. In some embodiments, cleavage upstream and downstream of the target site (e.g., by zinc finger nucleases, TALENs, or CRISPR) can result in a DNA double-strand break, and homologous recombination is used to replace the endogenous mouse ANGPTL4 sequence with a human or humanized ANGPTL4 sequence to form a chimeric ANGPTL4 gene (e.g., a humanized ANGPTL4 gene).

[0186] Therefore, in some embodiments, the method for preparing a genetically modified humanized animal comprises replacing a nucleic acid sequence encoding an endogenous ANGPTL4 region with a nucleotide sequence encoding a corresponding region of human ANGPTL4 at an endogenous ANGPTL4 locus (or site). The replaced sequence may include a region (e.g., a portion or all of) exons 1-7 of a human ANGPTL4 gene. In some embodiments, the sequence comprises a portion of exon 1, all of exons 2-6, and a portion of exon 7 of a human ANGPTL4 gene, or a portion of exon 1 to a portion of exon 7 of a human ANGPTL4 gene (e.g., a nucleotide sequence of positions 168-1388 of NM_139314.3). In some embodiments, the sequence comprises a nucleotide sequence upstream of the 5'UTR of a human ANGPTL4 gene, all of exons 1-7, and a nucleotide sequence downstream of the 3'UTR of an exon (e.g., a nucleotide sequence of positions 1-1872 of NM_139314.3). In some embodiments, the sequence includes a portion of exon 1 and a portion of exon 7 of an endogenous ANGPTL4 gene of a non-human animal (eg, a nucleotide sequence of positions 1-183 and / or 1416-1903 of NM_020581.2).

[0187] The present invention also provides a method for establishing an ANGPTL4 gene humanized animal model, comprising the following steps:

[0188] (a) providing cells (e.g., fertilized egg cells) based on the method described in the present application;

[0189] (b) culturing the cells (preferably culturing the cells in a liquid culture medium);

[0190] (c) transplanting the cultured cells into the oviduct or uterus of a recipient female non-human mammal, allowing the cells to develop in the uterus of the female non-human mammal;

[0191] (d) identifying germline transmission in offspring of the genetically modified humanized non-human mammal of the pregnant female in step (c).

[0192] In some embodiments, the non-human mammal in the above methods is a mouse (eg, a C57BL / 6 mouse).

[0193] In some embodiments, the non-human mammal in step (c) is a female with pseudopregnancy (or pregnancy).

[0194] In some embodiments, the fertilized eggs used in the above methods are C57BL / 6 fertilized eggs. Other fertilized eggs that can also be used in the methods described herein include, but are not limited to, FVB / N fertilized eggs, BALB / c fertilized eggs, DBA / 1 fertilized eggs, and DBA / 2 fertilized eggs.

[0195] The fertilized egg can be from any non-human animal, such as any non-human animal described herein. In some embodiments, the fertilized egg cell is derived from a rodent. The gene construct can be introduced into the fertilized egg by microinjection. For example, by culturing the fertilized egg after microinjection, the cultured fertilized egg can be transferred to a pseudopregnant non-human animal, and then the pseudopregnant non-human animal gives birth to a non-human mammal, thereby producing the non-human mammal mentioned in the above method.

[0196] In some embodiments, the method for preparing a genetically modified non-human animal comprises modifying the coding frame of the ANGPTL4 gene of the non-human animal, for example, by replacing the nucleic acid sequence encoding the corresponding region of the endogenous ANGPTL4 (e.g., genomic DNA, CDS or cDNA sequence) with a nucleotide sequence encoding human ANGPTL4 under the control of the endogenous regulatory elements of the ANGPTL4 gene of the non-human animal or the human regulatory elements. For example, one or more functional region sequences of the ANGPTL4 gene of the non-human animal can be knocked out or inserted into a sequence, so that the endogenous ANGPTL4 protein of the non-human animal cannot be expressed or the expression level is reduced. In some embodiments, the coding frame of the modified non-human animal ANGPTL4 gene can be all or part of the nucleotide sequence of exon 1 to exon 7 of the ANGPTL4 gene of the non-human animal. In some embodiments, the coding frame of the modified non-human animal ANGPTL4 gene can be the nucleotide sequence from the upstream 5'UTR of the ANGPTL4 gene of the non-human animal to the downstream 3'UTR of the ANGPTL4 gene of the non-human animal.

[0197] In some embodiments, the method of preparing a genetically modified non-human animal comprises inserting a nucleotide sequence encoding a human or humanized ANGPTL4 protein and / or an auxiliary sequence after the endogenous or human regulatory elements of the endogenous ANGPTL4 locus of the non-human animal. In some embodiments, the auxiliary sequence can be a stop codon, so that the ANGPTL4 gene humanized animal model can express the human or humanized ANGPTL4 protein in vivo, but does not express the ANGPTL4 protein of the non-human animal. In some embodiments, the auxiliary sequence comprises WPRE (WHP post-transcriptional response element), loxP, STOP and / or polyA.

[0198] In some embodiments, methods for preparing a genetically modified non-human animal include using the above-described vectors, e.g., a targeting vector and / or an sgRNA vector.

[0199] In some embodiments, a method for making a transgenic non-human animal comprises:

[0200] (1) providing a plasmid comprising a human ANGPTL4 gene fragment, wherein the plasmid is flanked by a 5' homology arm and a 3' homology arm, wherein the 5' homology arm and the 3' homology arm target endogenous ANGPTL4 of a non-human animal;

[0201] (2) providing one or more guide RNAs (sgRNAs) targeting an endogenous ANGPTL4 gene of a non-human animal;

[0202] (3) modifying the genome of a fertilized egg or embryonic stem cell by using the plasmid of step (1), the sgRNA of step (2) and Cas9;

[0203] (4) transplanting the fertilized egg obtained in step (3) into the oviduct of a pseudo-pregnant female non-human animal (e.g., a mouse), or transplanting the embryonic stem cells obtained in step (3) into a blastocyst, and then transplanting the blastocyst into the oviduct of a pseudo-pregnant female non-human animal (e.g., a mouse) to produce an offspring non-human animal (e.g., a mouse) that functionally expresses the humanized ANGPTL4 protein.

[0204] In some embodiments, the method further comprises (5) mating the offspring mice obtained in step (4) to obtain homozygous non-human animals (eg, mice).

[0205] In some embodiments, fertilized eggs are modified by CRISPR with sgRNAs targeting a 5'-terminal targeting site and a 3'-terminal target site.

[0206] In some embodiments, the sequence encoding the humanized ANGPTL4 protein is operably linked to endogenous or human regulatory elements at the endogenous ANGPTL4 locus of the non-human animal.

[0207] In some embodiments, the genetically modified non-human animal does not express endogenous ANGPTL4 protein.

[0208] In some embodiments, a method for making a transgenic non-human animal comprises:

[0209] (1) providing a plasmid comprising a human or chimeric ANGPTL4 gene fragment, the plasmid being flanked by a 5' homology arm and a 3' homology arm, wherein the 5' and 3' homology arms target endogenous ANGPTL4 of a non-human animal;

[0210] (2) providing one or more guide RNAs (sgRNAs) targeting an endogenous ANGPTL4 gene of a non-human animal;

[0211] (3) Modifying the genome of a fertilized egg or embryonic stem cell by inserting the human or chimeric ANGPTL4 gene fragment into the genome.

[0212] In some embodiments, the construction method comprises replacing the upstream nucleotide sequence from the 5'UTR side to the downstream nucleotide sequence from the 3'UTR side of the endogenous ANGPTL4 gene of a non-human animal with the upstream nucleotide sequence from the 5'UTR side to the downstream nucleotide sequence from the 3'UTR side of the human ANGPTL4 gene.

[0213] In some embodiments, the construction method comprises replacing the nucleotide sequence encoding SEQ ID NO: 1 or the amino acid sequence shown in positions 24-410 of SEQ ID NO: 1 in the genome of a non-human animal with a nucleotide sequence encoding a human or humanized ANGPTL4 protein or a human or humanized ANGPTL4 gene.

[0214] In some embodiments, the construction method comprises replacing the nucleotide sequence encoding SEQ ID NO: 1 or the amino acid sequence shown at positions 24-410 of SEQ ID NO: 1 in the genome of a non-human animal with the genomic DNA sequence, cDNA sequence or CDS sequence of human ANGPTL4.

[0215] In some embodiments, the construction method includes replacing the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 1 at positions 24-410 in the genome of a non-human animal with the nucleotide sequence encoding SEQ ID NO: 2 or SEQ ID NO: 2 at positions 31-406.

[0216] In some embodiments, the construction method comprises replacing the nucleotide sequence encoding SEQ ID NO: 1 or the amino acid sequence shown at positions 24-410 of SEQ ID NO: 1 in the genome of a non-human animal with SEQ ID NO: 5 or 16.

[0217] In some embodiments, the construction method further comprises mating, in vitro fertilization or direct gene editing of the non-human animal with humanized ANGPTL4 gene with other genetically modified non-human animals, and screening to obtain multi-gene modified non-human animals.

[0218] In some embodiments, the other genetically modified non-human animals include humanized non-human animals of one or a combination of two or more genes CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 and CTLA-4.

[0219] In some embodiments, each of the multiple genes modified in the genome of the polygenic modified non-human animal is homozygous or heterozygous for the endogenous modified locus.

[0220] In some embodiments, the non-human animal can be selected from any non-human animal that can be gene-edited to produce humanized genes, such as rodents, pigs, rabbits, monkeys, etc.

[0221] In some embodiments, the non-human animal is a non-human mammal. In some embodiments, the non-human mammal is a rodent. In some embodiments, the rodent is a rat or a mouse.

[0222] In some embodiments, the non-human animal is an immunodeficient non-human mammal. In some embodiments, the immunodeficient non-human mammal is an immunodeficient rodent, an immunodeficient pig, an immunodeficient rabbit, or an immunodeficient monkey. In some embodiments, the immunodeficient rodent is an immunodeficient mouse or rat. In some embodiments, the immunodeficient mouse is a NOD-Prkdc scid IL-2rγ null Mouse, NOD-Rag 1 - / - -IL2rg - / - Mouse, Rag 2 - / - -IL2rg - / - mice, NOD / SCID mice or nude mice.

[0223] Use of genetically modified non-human animals

[0224] Replacing a non-human animal gene with a homologous or orthologous human gene or human sequence or inserting a homologous or orthologous human gene or human sequence into a non-human animal at an endogenous locus of the non-human animal and under the control of endogenous or human regulatory elements (e.g., 5'UTR, 3'UTR, and / or promoter) can produce a non-human animal with qualities and characteristics that may be significantly different from typical knockout plus transgenic non-human animals. In typical knockout plus transgenic non-human animals, the endogenous locus is removed or destroyed, and the full human transgene is inserted into the genome of the animal and may be randomly integrated into the genome. Typically, the location of the integrated transgene is unknown; the expression of human proteins is measured by transcription of human gene and / or protein assays and / or functional assays. In human transgenes, the upstream and / or downstream of the human sequence provide suitable support for the expression and / or regulation of the transgene.

[0225] Genetically modified non-human animals that express human or humanized ANGPTL4 proteins, e.g., in a physiologically appropriate manner, provide a variety of uses, including, but not limited to, developing treatments for human diseases and disorders, and evaluating the toxicity and / or efficacy of these human treatments in animal models.

[0226] The present invention also provides an application of the above-mentioned ANGPTL4 gene-modified non-human animal and the non-human animal obtained by any of the above-mentioned construction methods.

[0227] In some embodiments, the application comprises:

[0228] A) Applications in the development of products for ANGPTL4-related immune processes involving human cells;

[0229] B) Application as a model system related to ANGPTL4 for pharmacological, immunological, microbiological and medical research;

[0230] C) applications involving the production and use of animal experimental disease models for the study of ANGPTL4-related etiology and / or for the development of diagnostic strategies and / or for the development of therapeutic strategies;

[0231] D) in vivo screening, efficacy testing, efficacy assessment, validation or evaluation of human ANGPTL4 signaling pathway modulators; or,

[0232] E) To study the function of the ANGPTL4 gene, the drugs targeting the human ANGPTL4 target site and their efficacy, and the application of drugs related to ANGPTL4 in tumors, metabolic diseases, inflammation, and immune-related diseases.

[0233] The present invention provides a non-human animal expressing a human or humanized ANGPTL4 protein, which can be used for screening of human ANGPTL4-specific modulators. In some embodiments, the non-human animal is a human disease animal model. For example, the disease is genetically induced (knock-in or knock-out). In different embodiments, the genetically modified non-human animal also comprises a compromised immune system, such as a genetically modified human-derived tissue xenograft, including a human solid tumor (e.g., breast cancer) or a blood cell tumor (e.g., a lymphocyte tumor, a B or T cell tumor).

[0234] In some embodiments, the anti-ANGPTL4 antibodies block or inhibit ANGPTL4-mediated signaling pathways. In some embodiments, the anti-ANGPTL4 antibodies described herein can block the interaction between ANGPTL4 complexes, thereby inhibiting the ANGPTL4 signaling pathway.

[0235] In some embodiments, genetically modified non-human animals can be used to determine the therapeutic agent (e.g., anti-ANGPTL4 antibody, polypeptide drug or nucleic acid drug, such as ASO) in treating diseases associated with ANGPTL4 expression or abnormal expression (e.g., overexpression). In some embodiments, the disease includes a disease for which targeting ANGPTL4 or downregulating the expression of ANGPTL4 is beneficial for treatment. In some embodiments, the disease includes tumors, inflammation, immune-related diseases or metabolic diseases.

[0236] In some embodiments, the immune-related diseases include, but are not limited to, one or more of GVHD (graft versus host disease), psoriasis, allergies, asthma, atopic dermatitis, myocarditis, nephritis, hepatitis (preferably non-alcoholic fatty liver disease), systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain, or neurological disorders.

[0237] In some embodiments, the inflammation includes, but is not limited to, one or more of myocarditis, nephritis, hepatitis, rheumatoid arthritis, atopic dermatitis or ulcerative colitis.

[0238] In some embodiments, the metabolic disease comprises one or more of obesity, non-alcoholic fatty liver disease (NAFLD), or atherosclerosis.

[0239] In some embodiments, a therapeutic agent (e.g., an anti-ANGPTL4 antibody, a polypeptide drug, or a nucleic acid drug, such as an ASO) is administered to a non-human animal, wherein the non-human animal has cancer or a tumor, and the inhibitory effect of the therapeutic agent on the cancer or tumor is detected. In some embodiments, the detection includes measuring the size and / or proliferation rate of tumor cells. In some embodiments, the detection method includes vernier caliper measurement, flow cytometry, and / or in vivo animal imaging detection. In some embodiments, the detection includes assessing individual body weight, fat mass, activation pathways, neuroprotective activity, or metabolic changes, and the metabolic changes include changes in food consumption or water consumption.

[0240] In some embodiments, the tumor cells include one or more cancer cells injected into a non-human animal (e.g., cancer cells derived from a human or non-human animal). In some embodiments, the therapeutic agent inhibits the ANGPTL4 signaling pathway. In some embodiments, the therapeutic agent does not inhibit the ANGPTL4 signaling pathway.

[0241] In some embodiments, the genetically modified non-human animals can be used to detect whether an anti-ANGPTL4 antibody is an agonist or an antagonist. In some embodiments, the methods described herein can be used to detect the function of a therapeutic agent (e.g., an anti-ANGPTL4 antibody, a polypeptide drug, or a nucleic acid drug, such as an ASO), for example, whether the therapeutic agent can upregulate an immune response or downregulate an immune response, and / or whether the therapeutic agent can induce complement-mediated cytotoxicity (CMC) or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the genetically modified non-human animals can be used to determine the effective dose of a therapeutic agent for treating a disease in a subject (e.g., an ANGPTL4-related tumor, a metabolic disease, inflammation, an immune-related disease). The inhibitory effect on tumors can also be determined by methods known in the art, for example, by measuring the tumor volume in the animal, and / or determining the tumor (volume) inhibition rate (TGI). TV ). The tumor growth inhibition rate can be calculated using the formula TGI TV (%) = (1-TVt / TVc) × 100, where TVt and TVc are the average tumor volumes (or weights) of the treatment and control groups.

[0242] In some embodiments, therapeutic agents (e.g., anti-ANGPTL4 antibodies, polypeptide drugs, or nucleic acid drugs, such as ASOs) can be used to treat various cancers. The term "cancer" as used herein refers to cells with autonomous growth capacity, i.e., an abnormal state or condition characterized by rapid cell growth and proliferation. The term is intended to include all types of cancerous growth or carcinogenic processes, metastatic tissues, or malignantly transformed cells, tissues, or organs, regardless of the histopathological type or invasive stage. The term "tumor" as used herein includes, but is not limited to, lymphoma, non-small cell lung cancer, cervical cancer, leukemia, ovarian cancer, nasopharyngeal cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, gastric cancer, bladder cancer, brain glioma, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreatic cancer, liver and bile duct cancer, esophageal cancer, kidney cancer, thyroid cancer, head and neck cancer, testicular cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, and sarcoma. Wherein, the leukemia is selected from acute lymphocytic (lymphoblastic) leukemia, acute myeloid leukemia, myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, plasma cell leukemia and chronic myeloid leukemia; the lymphoma is selected from Hodgkin's lymphoma and non-Hodgkin's lymphoma, including B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B cell lymphoma, T cell lymphoma and Waldenstrom's macroglobulinemia; the sarcoma is selected from osteosarcoma, Ewing's sarcoma, leiomyosarcoma, synovial sarcoma, soft tissue sarcoma, angiosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma and chondrosarcoma. In a specific embodiment of the present invention, the tumor includes but is not limited to melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, kidney cancer, breast cancer or endocrine cancer.

[0243] The present invention also provides a method for determining the toxicity of a therapeutic agent (e.g., an anti-ANGPTL4 antibody, a polypeptide drug, or a nucleic acid drug, such as an ASO). The method comprises administering a therapeutic agent to the non-human animal described above, and assessing the animal's weight change, red blood cell count, hematocrit, and / or hemoglobin. In some embodiments, the antibody can reduce red blood cells (RBC), hematocrit, or hemoglobin by 20%, 30%, 40%, or more than 50%. In some embodiments, the animal's body weight is at least 5%, 10%, 20%, 30%, or 40% less than a control group (e.g., the average body weight of an animal not treated with the antibody).

[0244] The present invention also provides an animal model constructed by the method described in the present application for developing products related to human cellular immune processes, producing human antibodies, or a model system for pharmacology, immunology, microbiology and medical research.

[0245] In some embodiments, an animal model generated by the methods described herein is provided for producing and utilizing animal experimental disease models of immune processes of human cells, studying pathogens, or developing new diagnostic strategies and / or therapeutic strategies.

[0246] The present invention also provides an animal model generated by the method described in the present application to screen, verify, evaluate or study the function of the ANGPTL4 gene, the effectiveness of drugs targeting human ANGPTL4 sites, and the effectiveness of drugs for ANGPTL4-related diseases, such as human ANGPTL4 antibodies, nucleic acid drugs (such as antisense oligonucleotide drugs, ASOs) and / or polypeptide drugs).

[0247] In some embodiments, the present application provides a method for verifying the in vivo efficacy of TCR-T, CAR-T and / or other immunotherapies (e.g., T cell adoptive transfer therapy). For example, the method comprises transplanting tumor cells of a human or non-human animal into a non-human animal described herein, and applying human CAR-T to a non-human animal having tumor cells of a human or non-human animal. The effectiveness of CAR-T therapy can be determined and evaluated. In some embodiments, the non-human animal is selected from an ANGPTL4 gene humanized non-human animal (or its progeny) prepared by the method described herein, a double or multiple humanized non-human animal (or its progeny) produced by the method described herein, a non-human animal expressing a human or humanized ANGPTL4 protein, or a tumor-bearing or inflammatory animal model described herein. In some embodiments, TCR-T, CAR-T and / or other immunotherapies can treat ANGPTL4-related diseases described herein. In some embodiments, TCA-T, CAR-T and / or other immunotherapies provide evaluation methods for treating ANGPTL4-related diseases described herein.

[0248] Non-human animal models with two or more human or chimeric (x) genes

[0249] The present invention also provides a non-human animal or transgenic animal model having two or more human or chimeric (x) genes. The non-human animal or animal model may comprise a human or chimeric (eg, humanized) ANGPTL4 gene and a sequence encoding an additional human or chimeric (x) protein.

[0250] In some embodiments, the additional human or chimeric (x) protein is at least one of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA-4. In some embodiments, the non-human animal or animal model also expresses at least one of human or humanized CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, and CTLA-4 proteins.

[0251] The present invention also provides a method for constructing a non-human animal with two or more human or chimeric (x) genes, the method comprising:

[0252] (1) Providing the above-mentioned construction method to obtain non-human animals or animal models;

[0253] (ii) mating, in vitro fertilization, or direct gene editing of the non-human animal or animal model provided in step (i) with other genetically modified non-human animals, and screening to obtain multi-gene modified non-human animals.

[0254] In some embodiments, the other genetically modified non-human animals include humanized non-human animals of one or a combination of two or more genes CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 and CTLA-4.

[0255] In some embodiments, ANGPTL4 humanization is performed directly on non-human animals with human or chimeric CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, and CTLA-4 gene modifications.

[0256] Since these proteins may be involved in different mechanisms, combination therapy targeting two or more of them may be a more effective treatment method. In fact, many related clinical trials are ongoing and have shown good results. Multigene modified non-human animal models can be used to determine the effectiveness of combination therapy targeting two or more proteins, for example, anti-ANGPTL4 antibodies, polypeptide drugs or nucleic acid drugs (the nucleic acid drugs such as ASOs, at least one of which, and additional therapeutic agents for treating cancer (tumors), inflammation, metabolic diseases or immune-related diseases (e.g., asthma or atopic dermatitis). The method includes administering to an animal at least one of an anti-ANGPTL4 antibody, polypeptide drug or nucleic acid drug (the nucleic acid drug such as ASO), and an additional therapeutic agent, wherein the animal suffers from a disease, and determining the effect of the combination therapy on the disease. In some embodiments, the additional therapeutic agent is a specific binding agent to CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TI GIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 and CTLA-4 antibodies. In some embodiments, the additional therapeutic agent is an anti-CTLA-4 antibody (e.g., ipilimumab), an anti-PD-1 antibody (e.g., nivolumab) or an anti-PD-L1 antibody. In some embodiments, the non-human animal described above further comprises a sequence encoding a human or humanized PD-1, a sequence encoding a human or humanized PD-L1, or a sequence encoding a human or humanized CTLA-4. In some embodiments, the additional therapeutic agent is an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab), an anti-PD-L1 antibody and / or an anti-CTLA-4 antibody. In some embodiments, the tumor described above comprises one or more tumor cells expressing PD-L1 and / or PD-L2.

[0257] In some embodiments, combined therapy (combination therapy) is used to treat various cancers described in the present application, for example, one or more of melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, renal cancer, breast cancer or endocrine cancer. In some embodiments, combined therapy is designed to treat immune-related diseases described in the present application, such as psoriasis. In some embodiments, the method described in the present application can be used to evaluate combined therapy with some other methods. The method for treating cancer that can be used alone or in combination with the method described in the present application includes, for example, treating a subject with chemotherapy, for example, camphor alkali, doxorubicin, cisplatin, carboplatin, procarbazine, methylclorazepate, cyclophosphamide, doxorubicin, ifosamide, melphalan, chloramphenicol, thiophene, nitrosourea, dacrynic acid, daunorubicin, bleomycin, primycin, mitomycin, etoposide, verapamil, podophyllotoxin, tamoxifen, paclitaxel, transplatinum, 5-fluorouric acid, vincristine, vinblastine and / or methotrexate. Alternatively, or in addition, the method can include performing surgery on the subject to remove at least a portion of the cancer, for example, removing a portion or all of a tumor from the patient. BRIEF DESCRIPTION OF THE DRAWINGS

[0258] Figure 1 : Schematic diagram comparing the mouse ANGPTL4 locus and the human ANGPTL4 locus (not to scale);

[0259] Figure 2 : Schematic diagram of ANGPTL4 gene targeting strategy and targeting vector V1 design (not to scale);

[0260] Figure 3 : Southern blot identification results of F1 generation of ANGPTL4 gene humanized mice, where WT is the wild-type control;

[0261] Figure 4 : RT-PCR test results, where + / + is wild-type C57BL / 6 mice, H / H is ANGPTL4 gene humanized homozygous mice, and H2O is water control;

[0262] Figure 5 :Western blot test results, where + / + is wild-type C57BL / 6 mice, H / H is ANGPTL4 gene humanized homozygous mice;

[0263] Figure 6 : Schematic diagram of ANGPTL4 gene targeting strategy and targeting vector V2 design (not to scale);

[0264] Figure 7 : Schematic diagram of ANGPTL4 gene targeting strategy and targeting vector V3 design (not to scale);

[0265] Figure 8 : Southern blot identification results of F1 generation of ANGPTL4 gene humanized mice, where WT is the wild-type control;

[0266] Fig. 9 : RT-PCR test results, where + / + is wild-type C57BL / 6 mice, H / + is ANGPTL4 gene humanized heterozygous mice, and H2O is water control;

[0267] Fig.10 : Schematic diagram of ANGPTL4 gene targeting strategy and targeting vector V4 design (not to scale);

[0268] Fig.11 : ELISA test results, where + / + is wild-type C57BL / 6 mice, and H / H is ANGPTL4 gene humanized homozygous mice;

[0269] Fig.12 : q-PCR test results, in which the G1 group was injected with PBS and the G2 group was injected with a nucleic acid drug targeting human ANGPTL4. DETAILED DESCRIPTION

[0270] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0271] Materials and methods

[0272] In each of the following examples, equipment and materials were obtained from the following companies:

[0273] C57BL / 6 mice and Flp transgenic mice were purchased from the National Rodent Laboratory Animal Seed Center, China Food and Drug Inspection Institutes;

[0274] StuI, AseI, and BsrGI enzymes were purchased from NEB with catalog numbers R0187S, R0526S, and R3575S;

[0275] β-actin Mouse mAb was purchased from Beyotime with the catalog number AF0003.

[0276] Example 1 Method for constructing ANGPTL4 gene humanized mice

[0277] A schematic diagram of the comparison between the mouse ANGPTL4 gene (NCBI Gene ID: 57875, located at positions 33993874 to 34000549 of chromosome 17 NC_000083.7, based on transcript NM_020581.2 and its encoded protein NP_065606.2 (SEQ ID NO: 1)) and the human ANGPTL4 gene (NCBI Gene ID: 51129, located at positions 8364155 to 8374370 of chromosome 19 NC_000019.10, based on transcript NM_139314.3 and its encoded protein NP_647475.1 (SEQ ID NO: 2)) is shown in FIG. Figure 1 shown.

[0278] In order to achieve the purpose of the present invention, a nucleotide sequence encoding a human ANGPTL4 protein can be introduced into the mouse endogenous ANGPTL4 locus, so that the mouse expresses a human or humanized ANGPTL4 protein. Specifically, using gene editing technology, under the control of the mouse ANGPTL4 gene regulatory element, a partial sequence of about 9.6 kb from exon 1 to exon 7 of the human ANGPTL4 gene is used to replace a partial sequence of about 6.0 kb from exon 1 to exon 7 of the mouse, thereby obtaining a humanized ANGPTL4 locus and achieving humanization of the mouse ANGPTL4 gene.

[0279] Design as Figure 2 The targeting strategy shown, Figure 2 The targeting vector contains homology arm sequences upstream and downstream of the mouse ANGPTL4 gene, and an A1 fragment containing a human ANGPTL4 fragment. The upstream 5' homology arm sequence (SEQ ID NO: 3) is identical to the nucleotide sequence of positions 34000367 to 34004613 of NCBI accession number NC_000083.7, and the downstream 3' homology arm sequence (SEQ ID NO: 4) is identical to the nucleotide sequence of positions 33989662 to 33993564 of NCBI accession number NC_000083.7. The nucleotide sequence of the human ANGPTL4 gene fragment (SEQ ID NO: 5) is identical to the nucleotide sequence of positions 8364322 to 8373886 of NCBI accession number NC_000019.10; the connection design of the upstream of the human ANGPTL4 fragment sequence and the mouse is:

[0280] The sequence " GAATC The last "C" in the sequence is the last nucleotide in the mouse. The "A" in is the first nucleotide of the human sequence. The downstream connection of the human ANGPTL4 fragment sequence and the mouse sequence is designed as:

[0281] The sequence " CCTAG "G" is the last nucleotide in the human sequence. The first "C" in is the first nucleotide of the mouse sequence.

[0282] The targeting vector also includes a resistance gene for positive clone screening, namely the neomycin phosphotransferase coding sequence Neo, and two site-specific recombination system Frt recombination sites arranged in the same direction are installed on both sides of the resistance gene to form a Neo cassette. The connection between the 5' end of the Neo cassette and the mouse ANGPTL4 gene is designed as follows:

[0283] The sequence " CAAGG The last "G" in the sequence is the last nucleotide of the mouse ANGPTL4 gene. The first "G" in is the first nucleotide of the Neo box; the connection between the 3' end of the Neo box and the mouse ANGP TL4 gene is designed as: The sequence " ACTTC The last "C" in the sequence is the last nucleotide of the Neo box. The first "G" in is the first nucleotide of the mouse ANGPTL4 gene. The mRNA sequence of the modified humanized ANGPTL4 is shown in SEQ ID NO: 13, and the expressed protein sequence is shown in SEQ ID NO: 2.

[0284] The construction of the targeting vector can be carried out by conventional methods, such as enzyme digestion and ligation. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector verified to be correct by sequencing is electroporated and transfected into the embryonic stem cells of C57BL / 6 mice, and the obtained cells are screened using the positive clone screening marker gene to screen the correct positive clone cells. The screened correct positive clone cells (black mice) are introduced into the separated blastocysts (white mice) according to the technology known in the art, and the obtained chimeric blastocysts are transferred to the culture medium for short-term culture and then transplanted into the oviduct of the recipient mother mouse (white mouse), and F0 generation chimeric mice (black and white) can be produced. F0 generation chimeric mice are backcrossed with wild-type mice to obtain F1 generation mice, and then the F1 generation heterozygous mice are mated with each other to obtain F2 generation homozygous mice. Positive mice can also be mated with Flp tool mice to remove the positive clone screening marker gene, and then mated with each other to obtain ANGPTL4 gene humanized homozygous mice.

[0285] In addition, CRISPR / Cas9 technology can be used for gene editing to further design Figure 6 The targeting strategy shown, Figure 6 The targeting vector V2 contains homology arm sequences upstream and downstream of the mouse ANGPTL4 gene, as well as a human ANGPTL4 fragment. The upstream 5' homology arm sequence (SEQ ID NO: 10) is identical to the nucleotide sequence of positions 34000367 to 34002091 of NCBI accession number NC_000083.7, and the downstream 3' homology arm sequence (SEQ ID NO: 11) is identical to the nucleotide sequence of positions 33993225 to 33994360 of NCBI accession number NC_000083.7. The nucleotide sequence of the human ANGPTL4 fragment (SEQ ID NO: 5) is identical to the nucleotide sequence of positions 8364322 to 8373886 of NCBI accession number NC_000019.10. The mRNA sequence of the modified humanized ANGPTL4 mouse is shown in SEQ ID NO: 13, and the expressed protein sequence is shown in SEQ ID NO: 2.

[0286] Conventional methods can be used to construct the targeting vector, such as enzyme digestion, ligation, direct synthesis, etc. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector that is verified to be correct by sequencing is used for subsequent experiments.

[0287] The target sequence (target site) determines the targeting specificity of sgRNA and the efficiency of inducing Cas9 to cut the target gene. Therefore, the selection and design of efficient and specific target sequence (target site) is a prerequisite for constructing sgRNA expression vectors. Design and synthesize sgRNA sequences that recognize target sites. The target sites of exemplary sgRNAs on the ANGPTL4 gene are as follows:

[0288] sgRNA1 target site (SEQ ID NO: 34): 5'-AGTAGCCGCGCATAGCACCAGGG-3';

[0289] sgRNA2 target site (SEQ ID NO: 35): 5′-CTCTATCCCACGGCAACGGCAGG-3′;

[0290] The activity of sgRNA was detected by UCA kit. After confirming that it could mediate efficient cutting efficiency, restriction sites were added to its 5' end and complementary chain to obtain forward oligonucleotide and reverse oligonucleotide sequences as shown in Table 3. After annealing, the annealing products were connected to pT7-sgRNA plasmid (the plasmid was linearized with BbsI first) to obtain expression vectors pT7-ANGPTL4-1 and pT7-ANGPTL4-2.

[0291] Table 3 sgRNA1 and sgRNA2 sequence list

[0292]

[0293] The pT7-sgRNA vector was synthesized by a plasmid synthesis company with a fragment DNA containing a T7 promoter and sgRNA scaffold (SEQ ID NO: 12) and connected to a backbone vector (source: Takara, item number 3299) by restriction digestion (EcoRI and BamHI) in sequence. The vector was sequenced and verified by a professional sequencing company, and the results showed that the target plasmid was obtained. The pronuclear fertilized eggs of mice, such as C57BL / 6 mice, were taken, and the in vitro transcription products of pT7-ANGPTL4-1 and pT7-ANGPTL4-2 plasmids (using the Ambion in vitro transcription kit, transcribed according to the instructions), the targeting vector and Cas9mRNA were premixed and injected into the cytoplasm or nucleus of the mouse fertilized eggs using a microinjector. Microinjection of fertilized eggs was performed according to the method in the Mouse Embryo Manipulation Experiment Manual (3rd Edition) (Andras Nagy, Chemical Industry Press, 2006). The injected fertilized eggs were transferred to culture medium for a short period of culture and then transplanted into the oviduct of the recipient mother mouse for development. The obtained mice (F0 generation) were hybridized and self-fertilized to expand the population and establish a stable ANGPTL4 gene humanized mouse strain.

[0294] The PCR method can be used to identify the somatic cell genotype of F1 generation mice, and the F1 generation PCR-positive mice are subjected to Southern blot detection to confirm whether there is random insertion. The mouse tail is cut to extract genomic DNA, and the genome is digested with StuI enzyme or AseI enzyme, transferred to a membrane, and hybridized. The 5' probe (5'Probe) and the 3' probe (3'Probe) are located on the 5' homology arm and the human ANGPTL4 genomic fragment, respectively. The specific probe and target fragment length are shown in Table 4 below), and the exemplary results are shown in Table 4 below. Figure 3 As shown, combined with the PCR and sequencing results, three mice numbered F1-1, F1-2 and F1-3 were positive mice. This indicates that the present method can be used to construct ANGPTL4 gene humanized mice that can be stably propagated and have no random insertions.

[0295] Table 4 Length of specific probes and target fragments

[0296] Restriction enzymes Probe Wild-type fragment size Recombinant sequence fragment size StuI 5'Probe 8.0kb 10.3kb AseI 3'Probe -- 20.6kb

[0297] 5'Probe-F (SEQ ID NO: 24): 5'-GGAGATGGCACATGGACTAGCATGG-3', 5'Probe-R (SEQ ID NO: 25): 5'-GCAGAGACAAAAGAGGACTGGGGTG-3';

[0298] 3'Probe-F (SEQ ID NO: 26): 5'-CCTGAGGGGCTCACCAGTCTCTGGG-3', 3'Probe-R (SEQ ID NO: 27): 5'-GAGCTGGGGGTTCCCAGCCCTAAT-3';

[0299] The expression of mRNA in ANGPTL4 humanized mice can be detected by RT-PCR. Specifically, 9-week-old C57BL / 6 mice (+ / +) and 9-week-old female ANGPTL4 humanized homozygous mice (H / H) prepared in this example were selected, including 1 wild-type mouse and 1 ANGPTL4 humanized mouse, and fasted for 16 hours. After euthanasia by cervical dislocation, adipose tissue was obtained and RT-PCR detection was performed using the primer sequences shown in Table 5 below. The test results are shown in FIG. Figure 4 As shown in the figure, only mouse ANGPTL4 mRNA was detected in wild-type C57BL / 6 mice, but no human ANGPTL4 mRNA was detected; only human ANGPTL4 mRNA was detected in ANGPTL4 gene homozygous mice.

[0300] Table 5 RT-PCR primer sequences and target fragment sizes

[0301]

[0302] In addition, the expression of human ANGPTL4 protein in ANGPTL4 humanized homozygous mice can be detected by conventional methods such as Western blot. Specifically, 2 9-week-old female C57BL / 6 mice (+ / +) and 2 9-week-old female ANGPTL4 gene humanized homozygous mice (H / H) prepared in this example were selected, including 1 wild-type mouse and 1 ANGPTL4 humanized mouse, and fasted for 16 hours. Adipose tissue was taken and detected using β-actin Mouse mAb and ANGPTL4 human-mouse cross antibody. The test results are as follows Figure 5 As shown. The results showed that ANGPTL4 protein could be detected in the adipose tissue of wild-type C57BL / 6 mice and ANGPTL4 humanized homozygous mice, and compared with the normal body state of mice, the ANGPTL4 levels of wild-type C57BL / 6 mice and ANGPTL4 humanized homozygous mice were higher in the fasting state. Combined with the above RT-PCR results, it was proved that human ANGPTL4 protein can be successfully expressed in ANGPTL4 gene humanized homozygous mice. Example 2 Method 2 for constructing ANGPTL4 gene humanized mice

[0303] In order to achieve the purpose of the present invention, a nucleotide sequence encoding a human ANGPTL4 protein can be introduced into the mouse endogenous ANGPTL4 locus, so that the mouse expresses a human or humanized ANGPTL4 protein. Specifically, using gene editing technology, under the control of the human ANGPTL4 gene regulatory element, the mouse 5'UTR upstream partial sequence to the 3'UTR downstream partial sequence of about 15.8 kb is replaced with the 5'UTR upstream partial sequence to the 3'UTR downstream partial sequence of about 11.5 kb, thereby obtaining a humanized ANGPTL4 locus and achieving humanization of the mouse ANGPTL4 gene.

[0304] Design as Figure 7 The targeting strategy shown, Figure 7The targeting vector contains homology arm sequences upstream and downstream of the mouse ANGPTL4 gene, and an A2 fragment containing a human ANGPTL4 fragment. The upstream 5' homology arm sequence (SEQ ID NO: 14) is identical to the nucleotide sequence of positions 34005293 to 34009497 of NCBI accession number NC_000083.7, and the downstream 3' homology arm sequence (SEQ ID NO: 15) is identical to the nucleotide sequence of positions 33989831 to 33993781 of NCBI accession number NC_000083.7. The nucleotide sequence of the human ANGPTL4 gene fragment (SEQ ID NO: 16) is identical to the nucleotide sequence of positions 8359155 to 8374947 of NCBI accession number NC_000019.10; the connection design of the upstream of the human ANGPT L4 fragment sequence and the mouse is:

[0305] The sequence " TAGGG The last "G" in the sequence is the last nucleotide in the mouse. The first "A" in is the first nucleotide of the human sequence.

[0306] The targeting vector also includes a resistance gene for positive clone screening, namely the neomycin phosphotransferase coding sequence Neo, and two site-specific recombination system Frt recombination sites arranged in the same direction are installed on both sides of the resistance gene to form a Neo cassette. The connection between the 5' end of the Neo cassette and the human ANGPTL4 gene is designed as follows:

[0307] The sequence " CTGTG The last "G" in the sequence is the last nucleotide of the human ANGPTL4 gene. The first "C" in is the first nucleotide of the Neo box; the connection between the 3' end of the Neo box and the mouse ANGPTL4 gene is designed as: The sequence " ACTT C The last "C" in the sequence is the last nucleotide of the Neo box. The first "T" in is the first nucleotide of the mouse ANG PTL4 gene. The mRNA sequence of the modified humanized ANGPTL4 is shown in SEQ ID NO: 21, and the expressed protein sequence is shown in SEQ ID NO: 2.

[0308] The construction of the targeting vector can be carried out by conventional methods, such as enzyme digestion and ligation. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector verified to be correct by sequencing is electroporated and transfected into the embryonic stem cells of C57BL / 6 mice, and the obtained cells are screened using the positive clone screening marker gene to screen the correct positive clone cells. The screened correct positive clone cells (black mice) are introduced into the separated blastocysts (white mice) according to the technology known in the art, and the obtained chimeric blastocysts are transferred to the culture medium for short-term culture and then transplanted into the oviduct of the recipient mother mouse (white mouse), and F0 generation chimeric mice (black and white) can be produced. F0 generation chimeric mice are backcrossed with wild-type mice to obtain F1 generation mice, and then the F1 generation heterozygous mice are mated with each other to obtain F2 generation homozygous mice. Positive mice can also be mated with Flp tool mice to remove the positive clone screening marker gene, and then mated with each other to obtain ANGPTL4 gene humanized homozygous mice.

[0309] In addition, CRISPR / Cas9 technology can be used for gene editing to further design Fig.10 The targeting strategy shown, Fig.10 The targeting vector V4 contains homology arm sequences upstream and downstream of the mouse ANGPTL4 gene, as well as a human ANGPTL4 fragment. The upstream 5' homology arm sequence (SEQ ID NO: 22) is identical to the nucleotide sequence of positions 34005293 to 34006620 of NCBI accession number NC_000083.7, and the downstream 3' homology arm sequence (SEQ ID NO: 23) is identical to the nucleotide sequence of positions 33992362 to 33993781 of NCBI accession number NC_000083.7. The nucleotide sequence of the human ANGPTL 4 fragment (SEQ ID NO: 16) is identical to the nucleotide sequence of positions 8359155 to 8374947 of NCBI accession number NC_000019.10. The connection design of the upstream of the human ANGPTL4 fragment sequence and the mouse is:

[0310] The sequence " TAGGG The last "G" in the sequence is the last nucleotide in the mouse. The first "A" in is the first nucleotide of the human sequence. The downstream connection of the human ANGPTL4 fragment sequence and the mouse sequence is designed as:

[0311] The sequence " CTGTG The last "G" in the sequence is the last nucleotide of the human sequence. The first "T" in is the first nucleotide of the mouse sequence.

[0312] The mRNA sequence of the modified humanized ANGPTL4 mouse is shown in SEQ ID NO: 21, and the expressed protein sequence is shown in SEQ ID NO: 2.

[0313] Conventional methods can be used to construct the targeting vector, such as enzyme digestion, ligation, direct synthesis, etc. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector that is verified to be correct by sequencing is used for subsequent experiments.

[0314] The target sequence determines the targeting specificity of sgRNA and the efficiency of inducing Cas9 to cut the target gene. Therefore, efficient and specific target sequence selection and design are the prerequisites for constructing sgRNA expression vectors. Design and synthesize sgRNA sequences that recognize target sites. The target sequence of exemplary sgRNA on the ANGPTL4 gene is as follows:

[0315] sgRNA3 target site (SEQ ID NO: 52): 5'-TCCCACTCTGGATAGGGCGGAGG-3';

[0316] sgRNA4 target site (SEQ ID NO: 53): 5′-TCGTATTCCCAGATCCGTTAAGG-3′;

[0317] The activity of sgRNA was detected by UCA kit. After confirming that it could mediate efficient cutting efficiency, restriction sites were added to its 5' end and complementary chain to obtain forward oligonucleotide and reverse oligonucleotide sequences as shown in Table 6. After annealing, the annealing products were connected to pT7-sgRNA plasmid (the plasmid was linearized with BbsI first) to obtain expression vectors pT7-ANGPTL4-3 and pT7-ANGPTL4-4.

[0318] Table 6 sgRNA3 and sgRNA4 sequence list

[0319]

[0320] The pT7-sgRNA vector was synthesized by a plasmid synthesis company with a fragment DNA containing a T7 promoter and sgRNA scaffold (SEQ ID NO: 12) and connected to a backbone vector (source: Takara, item number 3299) by restriction digestion (EcoRI and BamHI) in sequence. The vector was sequenced and verified by a professional sequencing company, and the results showed that the target plasmid was obtained. The pronuclear fertilized eggs of mice, such as C57BL / 6 mice, were taken, and the in vitro transcription products of pT7-ANGPTL4-3 and pT7-ANGPTL4-4 plasmids (using the Ambion in vitro transcription kit, transcribed according to the instructions), the targeting vector and Cas9mRNA were premixed and injected into the cytoplasm or nucleus of the mouse fertilized eggs using a microinjector. Microinjection of fertilized eggs was performed according to the method in the Mouse Embryo Manipulation Experiment Manual (3rd Edition) (Andras Nagy, Chemical Industry Press, 2006). The injected fertilized eggs were transferred to culture medium for a short period of culture and then transplanted into the oviduct of the recipient mother mouse for development. The obtained mice (F0 generation) were hybridized and self-fertilized to expand the population and establish a stable ANGPTL4 gene humanized mouse strain.

[0321] The PCR method can be used to identify the somatic cell genotype of F1 generation mice, and the F1 generation PCR-positive mice are subjected to Southern blot detection to confirm whether there is random insertion. The mouse tail is cut to extract genomic DNA, and the genome is digested with Asel enzyme or BsrGI enzyme, respectively, transferred to a membrane, and hybridized. The 5' probe (5'Probe) and the 3' probe (3'Probe) are located on the 5' homology arm and the human ANGPTL4 genomic fragment, respectively. The specific probe and target fragment length are shown in Table 7 below), and the exemplary results are shown in Table 7 below. Figure 8 As shown, combined with the PCR and sequencing results, 11 mice numbered F1-01 to F1-07 and F1-11 to F1-14 were positive mice. This indicates that the present method can be used to construct ANGPTL4 gene humanized mice that can be stably propagated and have no random insertions.

[0322] Table 7 Length of specific probes and target fragments

[0323] Restriction enzymes Probe Wild-type fragment size Recombinant sequence fragment size Asel 3'Probe -- 21.4kb BnB 5'Probe 7.9kb 6.6kb

[0324] 5'Probe-F (SEQ ID NO: 44): 5'-GGAACAAAGGGCATCAATGCAAAG-3', 5'Probe-R (SEQ ID NO: 45): 5'-GCAGCTATGCTCATCATGATCCCA-3';

[0325] 3'Probe-F (SEQ ID NO: 46): 5'-CCTTGTGTCTCCTCTTTCTGTTCT-3', 3'Probe-R (SEQ ID NO: 47): 5'-GGAACTCACCAAAAGTCCTTGCC-3';

[0326] The expression of mRNA in ANGPTL4 gene humanized mice can be detected by RT-PCR. Specifically, 6-week-old C57BL / 6 mice (+ / +) and 6-week-old male ANGPTL4 gene humanized heterozygous mice (H / +) prepared in this example were selected, and adipose tissue was obtained after euthanasia by cervical dislocation. RT-PCR detection was performed using the primer sequences shown in Table 8 below. The detection results are shown in FIG. Fig. 9 As shown. Fig. 9 It can be seen that human ANGPTL4 mRNA and mouse ANGPTL4 mRNA can be detected in ANGPTL4 gene humanized heterozygous mice, and only mouse ANGPTL4 mRNA is detected in wild-type C57BL / 6 mice, proving that the preparation of ANGPTL4 gene humanized heterozygous mice is successful.

[0327] Table 8 RT-PCR primer sequences and target fragment sizes

[0328]

[0329] The expression of human ANGPTL4 protein in positive mice can be confirmed by conventional detection methods, such as using ELISA method. The identification results are shown in Fig.11 . Fig.11 The results showed that compared with wild-type C57BL / 6 mice (+ / +), the expression of human ANGPTL4 protein could only be detected in homozygous ANGPTL4 humanized mice (H / H).

[0330] Example 3 Model construction and efficacy verification

[0331] The ANGPTL4 humanized mice prepared by the present application can be used to evaluate the efficacy of antisense oligonucleotide drugs (ASO) targeting human ANGPTL4. For example, ANGPTL4 humanized mice are taken and grouped for treatment. The treatment group is injected with ASO targeting human ANGPTL4, and the control group is injected with an equal volume of PBS. Peripheral blood of mice is taken at different times after administration, and the expression level of human ANGPTL4 protein in mice is detected using the HumanAngiopoietin-like 4Quantikine ELISA Kit. After euthanasia by cervical dislocation, the mouse liver is collected, and the expression level of human ANGPTL4 mRNA is detected by qPCR using an RNA extraction kit. The efficacy of nucleic acid drugs can be effectively evaluated by comparing the protein expression and mRNA expression of ANGPTL4. Specifically:

[0332] Taking the humanized homozygous (H / H) mice of ANGPTL4 prepared in Example 2 as an example, they were randomly divided into 2 groups (n=3, 8 weeks old in each group), and injected with PBS (control group, G1) or nucleic acid drugs targeting human ANGPTL4 (treatment group, G2) on the day of grouping. The expression level of human ANGPTL4 in the liver tissue of mice was detected by q-PCR method on the 7th day. Results (see Fig.12 ) showed that the relative expression level of human ANGPTL4 in the control group (G1) was 1.08, while the relative expression level in the treatment group (G2) was 0.36, indicating that the expression of human ANGPTL4 in mice in the treatment group (G2) could be inhibited by nucleic acid drugs targeting human ANGPTL4 (inhibition rate was 66.7%).

[0333] Example 4 Preparation of double-gene or multi-gene humanized mice

[0334] The humanized ANGPTL4 gene mouse prepared by the present method can also be used to prepare a multi-humanized mouse model. For example, in the above-mentioned Example 1 or 2, the embryonic stem cells used for microinjection can be selected from mice containing at least one gene modification of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 and CTLA-4, or, on the basis of humanized ANGPTL4 mice, mouse ES embryonic stem cells can be isolated and gene recombination targeting technology can be used to obtain a double humanized or multi-humanized mouse model. The homozygous or heterozygous ANGPTL4 mice obtained by this method can also be mated with other gene-modified mice, and their offspring can be screened. According to Mendel's law of inheritance, there is a certain probability of obtaining multigenic mice modified with the humanized ANGPTL4 gene and other genes, and then the heterozygotes can be mated with each other to obtain homozygous mice modified with two genes or multiple genes.

[0335] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0336] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0337] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.

Claims

1. A method for constructing a genetically modified non-human animal, It is characterized in that The genome of the non-human animal comprises at least one chromosome comprising a nucleotide sequence encoding a human or chimeric angiopoietin-like protein 4 (ANGPTL4) protein.

2. The construction method according to claim 1, It is characterized in that The chimeric ANGPTL4 protein is a humanized ANGPTL4 protein, wherein the humanized ANGPTL4 protein comprises at least 50 to at least 406 consecutive amino acid sequences identical to a human ANGPTL4 protein; Preferably, the amino acid sequence of the human or chimeric ANGPTL4 protein comprises SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406; or, comprises an amino acid sequence that differs from SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, comprises an amino acid sequence that is substituted, deleted and / or inserted with one or more amino acids as shown in SEQ ID NO: 2 or SEQ ID NO: 2, positions 31-406.

3. A method for constructing a genetically modified non-human animal, It is characterized in that At the non-human animal endogenous ANGPTL4 gene locus, the non-human animal endogenous ANGPTL4 gene is replaced with a nucleotide sequence comprising human ANGPTL4.

4. The construction method according to claim 3, It is characterized in that The nucleotide sequence of human ANGPTL4 comprises all or part of exon 1, all of exons 2-6 and / or all or part of exon 7 of the human ANGPTL4 gene, wherein the part of exon 1 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence; the part of exon 7 of the human ANGPTL4 gene preferably comprises at least 50 bp of continuous nucleotide sequence; Preferably, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence of the coding region of the human ANGPTL4 gene; further preferably, the nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene.

5. The construction method according to claim 4, It is characterized in that The nucleotide sequence of human ANGPTL4 comprises the 5'UTR and / or 3'UTR of the human ANGPTL4 gene; Preferably, the nucleotide sequence of human ANGPTL4 further comprises a nucleotide sequence of at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human ANGPTL4 gene and / or a nucleotide sequence of at least 50 bp of continuous nucleotides downstream of the 3'UTR of the human ANGPTL4 gene.

6. The construction method according to any one of claims 3 to 5, It is characterized in that The nucleotide sequence of human ANGPTL4 comprises the 5'UTR of human ANGPTL4 gene and at least 50 bp of continuous nucleotides upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of the human ANGPTL4 gene, and the 3'UTR of the human ANGPTL4 gene and at least 50 bp of continuous nucleotides downstream of the 3'UTR, or the nucleotide sequence of human ANGPTL4 comprises part of exon 1 to part of exon 7 of the human ANGPTL4 gene.

7. The construction method according to any one of claims 3 to 6, It is characterized in that The nucleotide sequence of human ANGPTL4 comprises the nucleotide sequence shown in SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence shown in SEQ ID NO: 5 or 16; or, comprises a nucleotide sequence that differs from the nucleotide sequence shown in SEQ ID NO: 5 or 16 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that substitutes, deletes and / or inserts one or more nucleotides from the nucleotide sequence shown in SEQ ID NO: 5 or 16.

8. The construction method according to any one of claims 3 to 7, It is characterized in that All or part of exon 1, all of exons 2-6, and / or all or part of exon 7 of the endogenous ANGPTL4 gene of the non-human animal are replaced, and preferably the replaced endogenous ANGPTL4 gene of the non-human animal further comprises at least 50 bp of continuous nucleotides upstream of the 5'UTR and / or at least 50 bp of continuous nucleotides downstream of the 3'UTR of the endogenous ANGPTL4 gene of the non-human animal; Preferably, the replaced endogenous ANGPTL4 gene of a non-human animal comprises the 5'UTR of the endogenous ANGPTL4 gene of a non-human animal and at least 50 bp of continuous nucleotides upstream of the 5'UTR, the nucleotide sequence from the start codon to the stop codon of the endogenous ANGPTL4 gene of a non-human animal, and the 3'UTR of the endogenous ANGPTL4 gene of a non-human animal and at least 50 bp of continuous nucleotides downstream of the 3'UTR; or, part of exon 1 to part of exon 7 of the endogenous ANGPTL4 gene of a non-human animal is replaced; Among them, the portion of exon 1 of the endogenous ANGPTL4 gene of a non-human animal preferably contains at least 50 bp of continuous nucleotide sequence; the portion of exon 7 of the endogenous ANGPTL4 gene of a non-human animal preferably contains at least 50 bp of continuous nucleotide sequence.

9. The construction method according to any one of claims 1 to 8, It is characterized in that The nucleotide sequence encoding the human or chimeric ANGPTL4 protein, or the nucleotide sequence of human ANGPTL4 is operably linked to endogenous regulatory elements of the endogenous ANGPTL4 gene locus or human regulatory elements (such as 5'UTR, 3'UTR and / or promoter); Preferably, the endogenous ANGPTL4 protein of the non-human animal is not expressed or is expressed at a reduced level compared to ANGPTL4 in wild-type animals; Preferably, the modified ANGPTL4 gene in the genome of the non-human animal is homozygous or heterozygous for the endogenous replaced locus.

10. The construction method according to any one of claims 1 to 9, It is characterized in that The non-human animal is a mammal, such as a monkey or a rodent (eg, a rat or a mouse).

11. The construction method according to any one of claims 1 to 10, It is characterized in that The mRNA transcribed from the modified nucleotide sequence of endogenous ANGPTL4 in the genome of the non-human animal comprises the nucleotide sequence shown in SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95% or 99% identical to the nucleotide sequence shown in SEQ ID NO: 13 or 21; or, comprises a nucleotide sequence that differs from the nucleotide sequence shown in SEQ ID NO: 13 or 21 by no more than 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 bp nucleotides; or, comprises a nucleotide sequence that replaces, deletes and / or inserts one or more nucleotides shown in the nucleotide sequence shown in SEQ ID NO: 13 or 21.

12. The construction method according to any one of claims 1 to 11, It is characterized in that The non-human animal also includes nucleotide sequences of human or chimeric proteins encoded by other genes, and the human or chimeric proteins include at least one of CFD, C3, C5, ANGPTL3, IL36R, IGF1R, TSLP, TLR8, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA-4.

13. A method for determining the effectiveness of a therapeutic agent in treating a disease, It is characterized in that The method comprises: 1) administering a therapeutic agent to a non-human animal obtained by the construction method according to any one of claims 1 to 12, wherein the non-human animal suffers from a disease; 2) Determine the inhibitory effect of the therapeutic agent on the disease.

14. The method according to claim 13, It is characterized in that The therapeutic agent includes an ANGPTL4 therapeutic agent, and the ANGPTL4 therapeutic agent preferably includes an anti-ANGPTL4 antibody, a polypeptide drug or a nucleic acid drug, and the nucleic acid drug is, for example, ASO; Preferably, the therapeutic agent further comprises an additional therapeutic agent, and the additional therapeutic agent preferably comprises one or more of anti-PD-1 antibody, anti-PD-L1 antibody or anti-CTLA-4 antibody.

15. The method according to claim 13 or 14, It is characterized in that The diseases include one or more of tumors, metabolic diseases, inflammation or immune-related diseases; Preferably, the tumor comprises one or more of melanoma, ovarian cancer, endometrial cancer, lung cancer, bladder cancer, kidney cancer, breast cancer or endocrine cancer; Preferably, the metabolic disease comprises one or more of obesity, non-alcoholic fatty liver disease (NAFLD) or atherosclerosis; Preferably, the immune-related diseases include one or more of GVHD (graft versus host disease), psoriasis, allergy, asthma, myocarditis, nephritis, hepatitis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, atopic dermatitis, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, ulcerative colitis, autoimmune liver disease, diabetes, pain or neurological disorders; Preferably, the inflammation includes one or more of myocarditis, nephritis, hepatitis, rheumatoid arthritis, atopic dermatitis or ulcerative colitis.

16. A method for determining the toxicity of an ANGPTL4 therapeutic agent, It is characterized in that The method comprises: 1) administering an ANGPTL4 therapeutic agent to a non-human animal obtained by the construction method according to any one of claims 1 to 12; 2) Determine the effects of ANGPTL4 therapeutics in non-human animals; Preferably, the determining of the effect of the ANGPTL4 therapeutic agent on the non-human animal comprises measuring the body weight or performing a blood test on the non-human animal; preferably, the blood test comprises one or more of red blood cell count, hematocrit or hemoglobin content.

17. A humanized ANGPTL4 gene, It is characterized in that The humanized ANGPTL4 gene comprises any of the following nucleotide sequences: A) a nucleotide sequence encoding SEQ ID NO: 2 or SEQ ID NO: 2, positions 31 to 406; B) one or more of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23; C) a nucleotide sequence that is at least 90% identical to one or more of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23; D) a nucleotide sequence that is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one or more of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.

18. A cell, tissue or organ, It is characterized in that The cell, tissue or organ comprises the humanized ANGPTL4 gene of claim 17.

19. Use of the construction method according to any one of claims 1 to 12 to obtain a non-human animal, the humanized ANGPTL4 gene according to claim 17, or the cell, tissue or organ according to claim 18, It is characterized in that The applications described include: A) Applications in the development of products for ANGPTL4-related immune processes involving human cells; B) Application as a model system related to ANGPTL4 for pharmacological, immunological, microbiological and medical research; C) applications involving the production and use of animal experimental disease models for the study of ANGPTL4-related etiology and / or for the development of diagnostic strategies and / or for the development of therapeutic strategies; D) in vivo screening, efficacy testing, efficacy assessment, validation or evaluation of human ANGPTL4 signaling pathway modulators; or, E) To study the function of the ANGPTL4 gene, the drugs targeting the human ANGPTL4 target site and their efficacy, and the application of drugs related to ANGPTL4 in tumors, metabolic diseases, inflammation, and immune-related diseases.

Citation Information

Cited By

  • ANGPTL3 gene humanized non-human animal as well as construction method and application thereof

    CN117384956A